

An Optical Coherence Tomography-Guided, Variable Dose Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration

American Journal of Ophthalmology

143, 566-583.e2

DOI: [10.1016/j.ajo.2007.01.028](https://doi.org/10.1016/j.ajo.2007.01.028)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Therapeutic effects of ranibizumab in neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2007, 2, 679-693.	0.3	1
2	Current Treatment of Age-Related Macular Degeneration. Optometry and Vision Science, 2007, 84, E559-E572.	0.6	29
3	Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?. British Journal of Ophthalmology, 2007, 91, 1259-1260.	2.1	7
4	Neovascular AMD: Out of the Forest and Into the Trees. Retina, 2007, 27, 655-661.	1.0	2
5	Ranibizumab According to Need: A Treatment for Age-related Macular Degeneration. American Journal of Ophthalmology, 2007, 143, 679-680.	1.7	223
6	Anti-VEGF Agents in the Treatment of Neovascular Age-related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday Patients. American Journal of Ophthalmology, 2007, 144, 627-637.e2.	1.7	210
7	Combination Therapy for Choroidal Neovascularisation. Drugs and Aging, 2007, 24, 979-990.	1.3	18
8	A new era in the treatment of age-related macular degeneration: from Factor X to antiangiogenesis. Expert Opinion on Therapeutic Patents, 2007, 17, 1351-1363.	2.4	3
9	Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration. Core Evidence, 2007, .	4.7	5
10	Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1877-1880.	1.0	42
14	Activity of neovascular lesions treated with bevacizumab: comparison between optical coherence tomography and fluorescein angiography. Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 811-815.	1.0	20
15	Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Effectiveness and Resource Allocation, 2008, 6, 12.	0.6	34
16	Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. Australasian journal of optometry, The, 2008, 91, 427-437.	0.6	60
17	Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clinical and Experimental Ophthalmology, 2008, 36, 748-755.	1.3	27
18	Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opinion on Pharmacotherapy, 2008, 9, 499-508.	0.9	46
19	Neovascular Age-Related Macular Degeneration. Drugs, 2008, 68, 1029-1036.	4.9	155
20	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. , 2008, , CD005139.		60
21	Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: A One-year Prospective Study. American Journal of Ophthalmology, 2008, 145, 249-256.e2.	1.7	188

#	ARTICLE	IF	CITATIONS
22	Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1. <i>American Journal of Ophthalmology</i> , 2008, 145, 239-248.e5.	1.7	766
23	Time Course of Morphologic Effects on Different Retinal Compartments after Ranibizumab Therapy in Age-related Macular Degeneration. <i>Ophthalmology</i> , 2008, 115, e39-e46.	2.5	41
24	Ranibizumab for the Treatment of Macular Edema Associated with Perfused Central Retinal Vein Occlusions. <i>Ophthalmology</i> , 2008, 115, e47-e54.	2.5	97
25	Anti-vascular Endothelial Growth Factor Pharmacotherapy for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2008, 115, 1837-1846.	2.5	132
26	Relationship Between Optical Coherence Tomography Retinal Parameters and Visual Acuity in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2008, 115, 2206-2214.	2.5	94
27	Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration. <i>Clinical Therapeutics</i> , 2008, 30, 2436-2451.	1.1	33
28	Shall we use Avastin [®] or Lucentis [®] for ocular neovascularization?. <i>Acta Ophthalmologica</i> , 2008, 86, 352-355.	0.6	6
31	Pharmacotherapy of age-related macular degeneration. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 3045-3052.	0.9	10
32	Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. <i>British Journal of Ophthalmology</i> , 2008, 92, 356-360.	2.1	68
33	Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Rat Retinas. <i>Diabetes</i> , 2008, 57, 1026-1033.	0.3	143
34	Intersession Repeatability of Visual Acuity Scores in Age-Related Macular Degeneration. , 2008, 49, 4347.		76
35	Early Clinical Experience with Ranibizumab for Occult and Minimally Classic Neovascular Membranes in Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2008, 222, 321-323.	1.0	18
36	Computer-Based Visual Evaluation as a Screening Tool after Intravitreal Injections of Vascular Endothelial Growth Factor Inhibitors. <i>Ophthalmologica</i> , 2008, 222, 364-368.	1.0	8
37	Pharmacotherapy for the Treatment of Choroidal Neovascularization Due to Age-Related Macular Degeneration. <i>Annual Review of Pharmacology and Toxicology</i> , 2008, 48, 61-78.	4.2	34
38	Bevacizumab Treatment for Subfoveal Choroidal Neovascularization From Causes Other Than Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2008, 126, 941.	2.6	73
39	Ranibizumab for neovascular age-related macular degeneration. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 1805-1814.	0.5	25
40	Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. <i>British Journal of Ophthalmology</i> , 2008, 92, 1035-1039.	2.1	64
41	Age-related macular degeneration: diagnosis and management. <i>British Medical Bulletin</i> , 2008, 85, 127-149.	2.7	93

#	ARTICLE	IF	CITATIONS
42	Quantitative Subanalysis of Optical Coherence Tomography after Treatment with Ranibizumab for Neovascular Age-Related Macular Degeneration. , 2008, 49, 3115.		126
44	A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. British Journal of Ophthalmology, 2008, 92, 1636-1641.	2.1	54
45	Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. British Journal of Ophthalmology, 2008, 92, 1081-1085.	2.1	43
46	RANIBIZUMAB (LUCENTIS) VERSUS BEVACIZUMAB (AVASTIN): MODELING COST EFFECTIVENESS. Evidence-Based Ophthalmology, 2008, 9, 42-43.	0.0	0
50	Value of polarisation-sensitive optical coherence tomography in diseases affecting the retinal pigment epithelium. British Journal of Ophthalmology, 2008, 92, 204-209.	2.1	67
51	An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration. Yearbook of Ophthalmology, 2008, 2008, 143-144.	0.0	0
52	COMBINATION PHOTODYNAMIC THERAPY AND INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN A NORTH INDIAN POPULATION. Retina, 2008, 28, 1296-1301.	1.0	4
53	The cost of vision for vitreoretinal interventions. Current Opinion in Ophthalmology, 2008, 19, 195-201.	1.3	2
54	COMBINATION PHOTODYNAMIC THERAPY AND INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AMD IN A NORTH INDIAN POPULATION. Retina, 2008, 28, 1132-1137.	1.0	10
56	INTRAVITREAL INJECTION OF BEVACIZUMAB COMBINED WITH VERTEPORFIN PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2008, 28, 675-681.	1.0	44
57	Treatment of age-related macular degeneration: focus on ranibizumab. Clinical Ophthalmology, 2008, 2, 1.	0.9	40
58	Differential Optical Densities of Intraretinal Spaces. , 2008, 49, 3529.		68
59	Expression of VLDLR in the Retina and Evolution of Subretinal Neovascularization in the Knockout Mouse Model's Retinal Angiomatous Proliferation. , 2008, 49, 407.		101
60	Quantitative Optical Coherence Tomography Findings in Various Subtypes of Neovascular Age-Related Macular Degeneration. , 2008, 49, 5048.		89
61	Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration. Clinical Ophthalmology, 2008, 2, 727.	0.9	9
62	Repeatability of Stratus Optical Coherence Tomography Measures in Neovascular Age-Related Macular Degeneration. , 2008, 49, 1084.		57
63	Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK. Clinical Ophthalmology, 2008, 2, 347.	0.9	5
64	Treatment of neovascular age-related macular degeneration: Current therapies. Clinical Ophthalmology, 2009, 3, 175.	0.9	28

#	ARTICLE	IF	CITATIONS
65	The Efficacy of Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration. Journal of Korean Ophthalmological Society, 2009, 50, 725.	0.0	9
66	Age-related macular degeneration: current treatments. Clinical Ophthalmology, 2009, 3, 155.	0.9	43
67	Exudative Age-Related Macular Degeneration: Current Therapies and Potential Treatments. Clinical Medicine Therapeutics, 2009, 1, CMT.S2225.	0.1	0
68	Evaluation of Ranibizumab-Induced Changes in High-Resolution Optical Coherence Tomographic Retinal Morphology and Their Impact on Visual Function. , 2009, 50, 2376.		61
69	Quality of the Threshold Algorithm in Age-Related Macular Degeneration: Stratus versus Cirrus OCT. , 2009, 50, 995.		30
70	Evaluation of Optical Coherence Tomography Retinal Thickness Parameters for Use in Clinical Trials for Neovascular Age-Related Macular Degeneration. , 2009, 50, 3378.		58
71	Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration. Arquivos Brasileiros De Oftalmologia, 2009, 72, 677-681.	0.2	3
72	Segmentation Error in Stratus Optical Coherence Tomography for Neovascular Age-Related Macular Degeneration. , 2009, 50, 399.		54
73	Pharmacotherapy of Retinal Diseases with Ranibizumab. Clinical Medicine Therapeutics, 2009, 1, CMT.S2371.	0.1	1
74	Activated VEGF Receptor Shed Into the Vitreous in Eyes With Wet AMD. JAMA Ophthalmology, 2009, 127, 613.	2.6	37
75	Identification of Optical Density Ratios in Subretinal Fluid as a Clinically Relevant Biomarker in Exudative Macular Disease. , 2009, 50, 3417.		49
76	Interobserver Agreement for the Detection of Optical Coherence Tomography Features of Neovascular Age-Related Macular Degeneration. , 2009, 50, 5405.		18
77	Comparison of Three Different Optical Coherence Tomography Models for Total Macular Thickness Measurements in Healthy Controls. Ophthalmologica, 2009, 223, 352-356.	1.0	24
78	Radiation therapy for neovascular age-related macular degeneration revisited. British Journal of Ophthalmology, 2009, 93, 279-280.	2.1	3
79	VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opinion on Investigational Drugs, 2009, 18, 1573-1580.	1.9	119
80	Quantitative Subanalysis of Cystoid Spaces and Outer Nuclear Layer Using Optical Coherence Tomography in Age-Related Macular Degeneration. , 2009, 50, 3366.		52
81	Limits of the retinal-mapping program in age-related macular degeneration. British Journal of Ophthalmology, 2009, 93, 274-275.	2.1	2
82	Outer Retinal Tubulation. JAMA Ophthalmology, 2009, 127, 1596.	2.6	273

#	ARTICLE	IF	CITATIONS
83	A STUDY COMPARING TWO PROTOCOLS OF TREATMENT WITH INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Evidence-Based Ophthalmology, 2009, 10, 94-95.	0.0	0
84	Age-related maculopathy â€“ Linking aetiology and pathophysiological changes to the ischaemia hypothesis. Progress in Retinal and Eye Research, 2009, 28, 63-86.	7.3	116
85	A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 1-11.	1.0	96
86	One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 899-906.	1.0	31
87	Intravitreal ranibizumab (Lucentis®) in the treatment of retinal angiomatous proliferation (RAP). Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 1165-1171.	1.0	52
89	One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups. Japanese Journal of Ophthalmology, 2009, 53, 389-395.	0.9	35
91	Bevacizumab: a new hope?. Eye, 2009, 23, 1755-1757.	1.1	0
92	Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice. Eye, 2009, 23, 1633-1640.	1.1	19
94	Bevacizumab (Avastin) for the Treatment of Ocular Disease. Survey of Ophthalmology, 2009, 54, 372-400.	1.7	125
95	Economic Implications of Current Age-Related Macular Degeneration Treatments. Ophthalmology, 2009, 116, 481-487.	2.5	27
96	Comparison of Spectral-Domain versus Time-Domain Optical Coherence Tomography in Management of Age-Related Macular Degeneration with Ranibizumab. Ophthalmology, 2009, 116, 947-955.	2.5	94
97	High-speed Ultrahigh Resolution Optical Coherence Tomography before and after Ranibizumab for Age-related Macular Degeneration. Ophthalmology, 2009, 116, 956-963.	2.5	42
98	Verteporfin Photodynamic Therapy Combined With Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2009, 116, 747-755.e1.	2.5	83
100	Tachyphylaxis and Bevacizumab. Ophthalmology, 2009, 116, 1831-1832.	2.5	8
102	Ranibizumab and Nonocular Hemorrhage. Ophthalmology, 2009, 116, 1593.	2.5	4
103	Intraocular Lenses in Children. Ophthalmology, 2009, 116, 1832-1833.	2.5	0
104	A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration. Ophthalmology, 2009, 116, 1731-1739.	2.5	305
105	Evaluation of Injection Frequency and Visual Acuity Outcomes for Ranibizumab Monotherapy in Exudative Age-related Macular Degeneration. Ophthalmology, 2009, 116, 1740-1747.	2.5	124

#	ARTICLE	IF	CITATIONS
106	Antiangiogenic Approaches to Age-Related Macular Degeneration Today. <i>Ophthalmology</i> , 2009, 116, S15-S23.	2.5	112
107	Etiology and Treatment of Macular Edema. <i>American Journal of Ophthalmology</i> , 2009, 147, 11-21.e1.	1.7	169
108	Effects of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Attributable to Age-related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2009, 147, 831-837.	1.7	100
109	A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study. <i>American Journal of Ophthalmology</i> , 2009, 148, 43-58.e1.	1.7	818
110	Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a Prospective Study. <i>American Journal of Ophthalmology</i> , 2009, 148, 59-65.e1.	1.7	71
111	Refractory Neovascular Age-related Macular Degeneration Secondary to Polypoidal Choroidal Vasculopathy. <i>American Journal of Ophthalmology</i> , 2009, 148, 70-78.e1.	1.7	159
112	Bilateral Simultaneous Intravitreal Injections in the Office Setting. <i>American Journal of Ophthalmology</i> , 2009, 148, 66-69.e1.	1.7	62
113	Quantification of Error in Optical Coherence Tomography Central Macular Thickness Measurement in Wet Age-related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2009, 148, 90-96.e2.	1.7	18
114	Comparison of Clinically Relevant Findings from High-Speed Fourier-Domain and Conventional Time-Domain Optical Coherence Tomography. <i>American Journal of Ophthalmology</i> , 2009, 148, 242-248.e1.	1.7	42
115	Results of One-Year's Treatment with Ranibizumab for Exudative Age-related Macular Degeneration in a Clinical Setting. <i>American Journal of Ophthalmology</i> , 2009, 148, 409-413.e1.	1.7	138
116	The As-Needed Treatment Strategy for Choroidal Neovascularization: A Feedback-Based Treatment System. <i>American Journal of Ophthalmology</i> , 2009, 148, 1-3.	1.7	64
117	Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial. <i>American Journal of Ophthalmology</i> , 2009, 148, 875-882.e1.	1.7	66
118	Three-dimensional high resolution OCT imaging of macular pathology. <i>Optics Express</i> , 2009, 17, 4037.	1.7	16
119	VEGF inhibitors for the treatment of neovascular age-related macular degeneration. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 637-646.	1.9	53
120	Retinal Angiography and Optical Coherence Tomography. , 2009, , .		18
121	Effect of intravitreal bevacizumab (Avastin [®]) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6 and 12 month results. <i>Acta Ophthalmologica</i> , 2010, 88, 594-600.	0.6	25
122	Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2010, 88, 420-425.	0.6	38
123	ONE-YEAR FOLLOW-UP OF COMBINED CUSTOMIZED THERAPY. PHOTODYNAMIC THERAPY AND BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 13-19.	1.0	14

#	ARTICLE	IF	CITATIONS
124	RETINAL FUNCTIONAL CHANGES MEASURED BY MICROPERIMETRY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS TREATED WITH RANIBIZUMAB. <i>Retina</i> , 2009, 29, 329-334.	1.0	37
125	EFFECT OF RANIBIZUMAB RETREATMENT FREQUENCY ON NEUROSENSORY RETINAL VOLUME IN NEOVASCULAR AMD. <i>Retina</i> , 2009, 29, 592-600.	1.0	13
126	TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 723-731.	1.0	170
127	Surgical Drainage of a Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration. <i>Retina</i> , 2009, 29, 704-707.	1.0	1
128	BEVACIZUMAB IN MACULAR EDEMA. <i>Retina</i> , 2009, 29, 941-948.	1.0	4
129	INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS. <i>Retina</i> , 2009, 29, 875-912.	1.0	215
130	MACULAR HEMORRHAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AFTER STABILIZATION WITH ANTIANGIOGENIC THERAPY. <i>Retina</i> , 2009, 29, 1074-1079.	1.0	17
131	ANTI-VEGF DRUGS AS THE 2009 FIRST-LINE THERAPY FOR CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA. <i>Retina</i> , 2009, 29, 1062-1066.	1.0	100
132	“TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION. <i>Retina</i> , 2009, 29, 1424-1431.	1.0	187
133	VITELLIFORM MACULAR DETACHMENT ASSOCIATED WITH BASAL LAMINAR DRUSEN IS UNRESPONSIVE TO VASCULAR ENDOTHELIAL GROWTH FACTOR BLOCKADE. <i>Retinal Cases and Brief Reports</i> , 2009, 3, 50-53.	0.3	2
134	Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 158-165.	1.3	110
135	INTRAVITREAL RANIBIZUMAB FOR THE PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA. <i>Retina</i> , 2009, 29, 750-756.	1.0	91
136	DISTORTION MAPS FROM PREFERENTIAL HYPERACUITY PERIMETRY ARE HELPFUL IN MONITORING FUNCTIONAL RESPONSE TO LUCENTIS THERAPY. <i>Retina</i> , 2009, 29, 1013-1018.	1.0	13
137	QUALITY ISSUES IN INTERPRETATION OF OPTICAL COHERENCE TOMOGRAMS IN MACULAR DISEASES. <i>Retina</i> , 2009, 29, 775-781.	1.0	41
138	Off-label drug use “ price analysis for Avastin® in ophthalmology. <i>International Journal of Pharmaceutical and Healthcare Marketing</i> , 2009, 3, 59-73.	0.7	2
139	RETINAL ANGIOMATOUS PROLIFERATION. <i>Retina</i> , 2009, 29, 732-739.	1.0	75
140	VITREOMACULAR TRACTION HINDERS THE EFFECTIVENESS OF ANTI-VEGF THERAPY IN A PATIENT WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retinal Cases and Brief Reports</i> , 2009, 3, 310-312.	0.3	0
142	VISUAL OUTCOME AFTER INTRAVITREAL RANIBIZUMAB FOR WET AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2010, 30, 436-442.	1.0	33

#	ARTICLE	IF	CITATIONS
143	COMPARING RETINAL THICKNESS MEASUREMENTS FROM CIRRUS SPECTRAL DOMAIN- AND STRATUS TIME DOMAIN-OPTICAL COHERENCE TOMOGRAPHY. <i>Retina</i> , 2010, 30, 596-606.	1.0	28
144	HEMORRHAGIC RECURRENCE OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION NOT PREDICTED BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY. <i>Retinal Cases and Brief Reports</i> , 2010, 4, 1-4.	0.3	1
145	COMBINED RANIBIZUMAB AND PHOTODYNAMIC THERAPY TO TREAT EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2010, 30, 1190-1196.	1.0	15
146	SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FOR IMAGING ERM, RETINAL EDEMA, AND VITREOMACULAR INTERFACE. <i>Retina</i> , 2010, 30, 246-253.	1.0	26
147	A COMPUTER-BASED DOCUMENTATION AND DATA MANAGEMENT SYSTEM OF CLINICALLY RELEVANT PARAMETERS DURING REPEATED ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR OR STEROID INJECTIONS. <i>Retina</i> , 2010, 30, 369-377.	1.0	2
148	ANGIOID STREAK-RELATED CHOROIDAL NEOVASCULARIZATION TREATED BY INTRAVITREAL RANIBIZUMAB. <i>Retina</i> , 2010, 30, 903-907.	1.0	22
149	RETINAL FUNCTIONAL CHANGES MEASURED BY MICROPERIMETRY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH RANIBIZUMAB. <i>Retina</i> , 2010, 30, 1017-1024.	1.0	44
150	Do We Need a New Classification for Choroidal Neovascularization in Age-Related Macular Degeneration?. <i>Retina</i> , 2010, 30, 1333-1349.	1.0	365
151	Bevacizumab (Avastin) conjugated microbubbles for anti-VEGF treatment of neovascular age-related macular degeneration. , 2010, , .		0
152	CORRELATION BETWEEN MORPHOLOGIC FEATURES ON SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY AND ANGIOGRAPHIC LEAKAGE PATTERNS IN MACULAR EDEMA. <i>Retina</i> , 2010, 30, 383-389.	1.0	87
153	LONG-TERM FOLLOW-UP FOR TYPE 1 (SUBRETINAL PIGMENT EPITHELIUM) NEOVASCULARIZATION USING A MODIFIED "TREAT AND EXTEND" DOSING REGIMEN OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. <i>Retina</i> , 2010, 30, 1368-1375.	1.0	105
154	Full Macular Translocation for Choroidal Neovascularization in the Era of Intravitreal Pharmacological Therapy. <i>Retina</i> , 2010, 30, 1739-1743.	1.0	3
155	ASSOCIATION OF FLUORESCIN ANGIOGRAPHIC FEATURES WITH VISUAL ACUITY AND WITH OPTICAL COHERENCE TOMOGRAPHIC AND STEREOSCOPIC COLOR FUNDUS PHOTOGRAPHIC FEATURES OF DIABETIC MACULAR EDEMA IN A RANDOMIZED CLINICAL TRIAL. <i>Retina</i> , 2010, 30, 1627-1637.	1.0	17
156	Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 467-476.	1.0	29
157	Relationship between angiographic and optical coherence tomographic (OCT) parameters for quantifying choroidal neovascular lesions. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 175-184.	1.0	26
158	Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 943-956.	1.0	26
159	Cirrus OCT versus Spectralis OCT: differences in segmentation in fibrovascular pigment epithelial detachment. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 1693-1698.	1.0	25
160	Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients. <i>Japanese Journal of Ophthalmology</i> , 2010, 54, 124-128.	0.9	7

#	ARTICLE	IF	CITATIONS
161	Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Japanese Journal of Ophthalmology, 2010, 54, 571-577.	0.9	29
162	Anti-VEGF Therapies and Blood Pressure: More Than Meets the Eye. Current Hypertension Reports, 2010, 12, 33-38.	1.5	11
163	Optical coherence tomography-based intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. International Ophthalmology, 2010, 30, 267-270.	0.6	9
164	Three-Dimensional Analysis of Retinal Layer Texture: Identification of Fluid-Filled Regions in SD-OCT of the Macula. IEEE Transactions on Medical Imaging, 2010, 29, 1321-1330.	5.4	186
165	Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system. Clinical Therapeutics, 2010, 32, 1343-1356.	1.1	27
166	Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. Eye, 2010, 24, 203-213.	1.1	23
167	Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices. Eye, 2010, 24, 775-783.	1.1	52
168	Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye, 2010, 24, 816-824.	1.1	38
169	Anti-VEGF therapy for choroidal neovascularisation previously treated with photodynamic therapy. Eye, 2010, 24, 1018-1023.	1.1	5
170	Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration. Eye, 2010, 24, 994-998.	1.1	33
171	Imaging chorioretinal vascular disease. Eye, 2010, 24, 422-427.	1.1	53
172	Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye, 2010, 24, 1708-1715.	1.1	71
173	Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Eye, 2010, 24, 1344-1351.	1.1	4
174	Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration. Eye, 2010, 24, 1193-1198.	1.1	33
175	Clinical Effect of Intravitreal Bevacizumab Injection in Myopic Choroidal Neovascularization. Journal of Korean Ophthalmological Society, 2010, 51, 359.	0.0	4
176	Analysis of Various Artifacts Produced by Spectral-Domain Optical Coherence Tomography Based on Macular Pathologies. Journal of Korean Ophthalmological Society, 2010, 51, 1084.	0.0	0
177	Primary Combined Photodynamic Therapy and Intravitreal Bevacizumab Injection for Neovascular Age-related Macular Degeneration. Journal of Korean Ophthalmological Society, 2010, 51, 35.	0.0	3
178	Three-Monthly Intravitreal Bevacizumab Injections for Neovascular Age-Related Macular Degeneration: Short-Term Visual Acuity Results. European Journal of Ophthalmology, 2010, 20, 740-744.	0.7	5

#	ARTICLE	IF	CITATIONS
179	Antiangiogenic drugs in the management of ocular diseases: Focus on anti-vascular endothelial growth factor. <i>Clinical Ophthalmology</i> , 2010, 4, 275.	0.9	16
180	Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2010, 4, 1271.	0.9	21
181	Identifying Early Recurrence of Choroidal Neovascularization during Treatment with Ranibizumab using C-Scan. <i>European Journal of Ophthalmology</i> , 2010, 20, 559-564.	0.7	2
182	Comparative Review of Ranibizumab versus Bevacizumab in the Treatment of Neovascular Age-related Macular Degeneration. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S2226.	0.4	0
183	Effects of Retinal Morphology on Contrast Sensitivity and Reading Ability in Neovascular Age-Related Macular Degeneration. , 2010, 51, 5431.		50
184	A VARIABLE-DOSING REGIMEN WITH INTRAVITREAL RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: YEAR 2 OF THE PRONTO STUDY. <i>Evidence-Based Ophthalmology</i> , 2010, 11, 26-27.	0.0	2
185	Reproducibility of Macular Thickness Measurements Using Cirrus SD-OCT in Neovascular Age-Related Macular Degeneration. , 2010, 51, 4788.		33
186	Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. <i>British Journal of Ophthalmology</i> , 2010, 94, 292-296.	2.1	67
187	Update on combination therapy in wet age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2010, 5, 681-688.	0.3	1
188	Bevacizumab for neovascular age-related macular degeneration (ABC trial): multicenter randomized double-masked study. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 747-752.	1.3	5
189	Alternative anti-VEGF treatment regimens in exudative age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2010, 5, 799-809.	0.3	0
190	Neovascular age-related macular degeneration and anti-VEGF nonresponders. <i>Expert Review of Ophthalmology</i> , 2010, 5, 35-41.	0.3	5
191	Asymmetrical thickness of parafoveal retina around surgically closed macular hole. <i>British Journal of Ophthalmology</i> , 2010, 94, 1545-1546.	2.1	38
192	Neovascular age-related macular degeneration. , 2010, , 128-132.		3
193	Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes. <i>British Journal of Ophthalmology</i> , 2010, 94, 1543-1545.	2.1	12
196	Response to Ranibizumab Therapy in Neovascular AMD – An Evaluation of Good and Bad Responders. <i>Klinische Monatsblätter Für Augenheilkunde</i> , 2010, 227, 244-248.	0.3	26
197	Combination therapy in exudative age-related macular degeneration: visual outcomes following combined treatment with photodynamic therapy and intravitreal bevacizumab. <i>Canadian Journal of Ophthalmology</i> , 2010, 45, 375-380.	0.4	9
199	Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy,) Tj ETQq1 1 0.784314 rgBT /Ove 45, 36-40.	0.4	24

#	ARTICLE	IF	CITATIONS
200	Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. <i>British Journal of Ophthalmology</i> , 2010, 94, 2-13.	2.1	262
201	The effects of nepafenac and amfenac on retinal angiogenesis. <i>Brain Research Bulletin</i> , 2010, 81, 310-319.	1.4	27
202	Agreement of Time-Domain and Spectral-Domain Optical Coherence Tomography with Fluorescein Leakage from Choroidal Neovascularization. <i>Ophthalmology</i> , 2010, 117, 1376-1380.	2.5	63
203	A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2010, 117, 2134-2140.	2.5	264
204	Repeatability and Reproducibility of Retinal Thickness Measurements by Optical Coherence Tomography in Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2010, 117, 1577-1584.	2.5	42
205	When Should Anti-Vascular Endothelial Growth Factor Treatment Be Stopped in Age-Related Macular Degeneration?. <i>American Journal of Ophthalmology</i> , 2010, 149, 4-6.e2.	1.7	3
206	Comparison of Intravitreal Triamcinolone Acetonide With Photodynamic Therapy and Intravitreal Bevacizumab with Photodynamic Therapy for Retinal Angiomatous Proliferation. <i>American Journal of Ophthalmology</i> , 2010, 149, 472-481.e1.	1.7	29
207	Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2. <i>American Journal of Ophthalmology</i> , 2010, 150, 315-324.e1.	1.7	301
208	Polypoidal Choroidal Vasculopathy Masquerading as Neovascular Age-Related Macular Degeneration Refractory to Ranibizumab. <i>American Journal of Ophthalmology</i> , 2010, 150, 666-673.	1.7	95
209	Retinal pigment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2010, 88, 736-741.	0.6	29
210	Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review. <i>Canadian Journal of Ophthalmology</i> , 2010, 45, 590-595.	0.4	35
211	Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone for Therapy-Resistant Exudative Age-Related Macular Degeneration. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2010, 26, 207-212.	0.6	18
212	Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration. <i>Pharmacoeconomics</i> , 2011, 29, 107-131.	1.7	40
213	A Review of Ranibizumab Clinical Trial Data in Exudative Age-Related Macular Degeneration and How to Translate It into Daily Practice. <i>Ophthalmologica</i> , 2011, 225, 112-119.	1.0	17
214	Spectral-Domain versus Time Domain Optical Coherence Tomography before and after Ranibizumab for Age-Related Macular Degeneration. <i>Ophthalmic Research</i> , 2011, 46, 152-159.	1.0	16
215	Management of Neovascular AMD. , 2011, , 79-98.		0
216	Review of Ranibizumab Trials for Neovascular Age-Related Macular Degeneration. <i>Seminars in Ophthalmology</i> , 2011, 26, 372-379.	0.8	33
217	Treatment of wet age-related macular degeneration with ranibizumab in clinical practice: Results and prognostic factors. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2011, 86, 254-259.	0.1	1

#	ARTICLE	IF	CITATIONS
218	Bevacizumab and Neovascular Age Related Macular Degeneration: Pathogenesis and Treatment. <i>Seminars in Ophthalmology</i> , 2011, 26, 69-76.	0.8	23
219	Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab. <i>Canadian Journal of Ophthalmology</i> , 2011, 46, 182-185.	0.4	18
220	Cystoid Macular Degeneration in Exudative Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2011, 152, 100-107.e2.	1.7	27
221	Flicker-induced changes in retinal blood flow assessed by Doppler optical coherence tomography. <i>Biomedical Optics Express</i> , 2011, 2, 1852.	1.5	30
223	Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease. <i>Survey of Ophthalmology</i> , 2011, 56, 95-113.	1.7	257
225	Effects of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Exudative Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2011, 118, 101-110.	2.5	85
226	Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial. <i>Ophthalmology</i> , 2011, 118, 111-118.	2.5	50
227	Characteristics of Patients Losing Vision after 2 Years of Monthly Dosing in the Phase III Ranibizumab Clinical Trials. <i>Ophthalmology</i> , 2011, 118, 523-530.	2.5	228
228	Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study. <i>Ophthalmology</i> , 2011, 118, 663-671.	2.5	366
229	The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing. <i>Ophthalmology</i> , 2011, 118, 1098-1106.	2.5	143
230	Predicting visual outcomes for macular disease using optical coherence tomography. <i>Saudi Journal of Ophthalmology</i> , 2011, 25, 145-158.	0.3	29
231	Intersession repeatability of optical coherence tomography measures of retinal thickness in early age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2011, 89, 229-234.	0.6	15
232	Reproducibility of retinal thickness measurements in patients with age-related macular degeneration using 3D Fourier-domain optical coherence tomography (OCT) (Topcon 3D-OCT1000). <i>Acta Ophthalmologica</i> , 2011, 89, 346-351.	0.6	30
233	Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. <i>Acta Ophthalmologica</i> , 2011, 89, 647-653.	0.6	20
234	Intrasession repeatability of optical coherence tomography measures in active neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2011, 89, 526-532.	0.6	7
235	Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. <i>New England Journal of Medicine</i> , 2011, 364, 1897-1908.	13.9	2,355
236	Age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2011, 5, 593.	0.9	9
237	Preferential Hyperacuity Perimeter as a Functional Tool for Monitoring Exudative Age-Related Macular Degeneration in Patients Treated by Intravitreal Ranibizumab. , 2011, 52, 7012.		19

#	ARTICLE	IF	CITATIONS
238	Early Multifocal Electroretinogram Findings during Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration. , 2011, 52, 3446.		11
239	The Role of Spectral-Domain OCT in the Diagnosis and Management of Neovascular Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2011, 42, S56-66.	0.4	59
240	Quantification of the Therapeutic Response of Intraretinal, Subretinal, and Subpigment Epithelial Compartments in Exudative AMD during Anti-VEGF Therapy. , 2011, 52, 1599.		77
241	The Effect of Triple Therapy on Patients with Subretinal Hemorrhage Accompanied by Choroidal Neovascularization. Journal of Korean Ophthalmological Society, 2011, 52, 442.	0.0	0
242	Combined Photodynamic Therapy and Intravitreal Bevacizumab Injection for Exudative Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Journal of Korean Ophthalmological Society, 2011, 52, 816.	0.0	0
243	Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration with a Predominantly Hemorrhagic Lesion. Journal of Korean Ophthalmological Society, 2011, 52, 838.	0.0	2
244	Remission and Dropout Rate of Anti-VEGF Therapy for Age-Related Macular Degeneration. European Journal of Ophthalmology, 2011, 21, 777-782.	0.7	45
245	Management of Neovascular Age-Related Macular Degeneration in Clinical Practice: Initiation, Maintenance, and Discontinuation of Therapy. Journal of Ophthalmology, 2011, 2011, 1-10.	0.6	5
246	As-Needed Treatment with Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration. European Journal of Ophthalmology, 2011, 21, 282-289.	0.7	14
247	One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study. Journal of Ophthalmology, 2011, 2011, 1-8.	0.6	46
248	Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Journal of Ophthalmology, 2011, 2011, 1-6.	0.6	23
249	Assessing Errors Inherent in OCT-Derived Macular Thickness Maps. Journal of Ophthalmology, 2011, 2011, 1-9.	0.6	48
250	Phacoemulsification in Eyes with Neovascular AMD Treated with Anti-VEGF Injections. European Journal of Ophthalmology, 2011, 21, 766-770.	0.7	18
251	Quality and Reproducibility of Retinal Thickness Measurements in Two Spectral-Domain Optical Coherence Tomography Machines. , 2011, 52, 6925.		48
252	Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Korean Journal of Ophthalmology: KJO, 2011, 25, 231.	0.5	8
253	ONE-YEAR OUTCOMES OF INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2011, 31, 846-856.	1.0	54
254	Retinal Angiomatous Proliferation. Current Drug Targets, 2011, 12, 199-205.	1.0	10
255	PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE). Retina, 2011, Publish Ahead of Print, 434-57.	1.0	181

#	ARTICLE	IF	CITATIONS
256	DIFFERENT DOSING OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION BECAUSE OF PATHOLOGIC MYOPIA. <i>Retina</i> , 2011, 31, 880-886.	1.0	35
257	ONE-YEAR RESULTS OF A FLEXIBLE REGIMEN WITH RANIBIZUMAB THERAPY IN MACULAR DEGENERATION. <i>Retina</i> , 2011, 31, 1261-1267.	1.0	22
258	Is Indocyanine Green Angiography Still Relevant?. <i>Retina</i> , 2011, 31, 209-221.	1.0	25
259	INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED. <i>Retina</i> , 2011, 31, 26-30.	1.0	143
260	Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration. <i>Current Drug Targets</i> , 2011, 12, 149-172.	1.0	56
261	Combined Treatment Modalities for Age Related Macular Degeneration. <i>Current Drug Targets</i> , 2011, 12, 182-189.	1.0	11
262	RANIBIZUMAB MONOTHERAPY VERSUS SINGLE-SESSION VERTEPORFIN PHOTODYNAMIC THERAPY COMBINED WITH AS-NEEDED RANIBIZUMAB TREATMENT FOR THE MANAGEMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2011, 31, 636-644.	1.0	20
263	A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. <i>Retina</i> , 2011, 31, 1449-1469.	1.0	131
264	Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration. <i>Current Drug Targets</i> , 2011, 12, 173-181.	1.0	95
265	Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 645-652.	1.0	34
266	Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 639-644.	1.0	47
267	Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 521-527.	1.0	6
268	Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 653-662.	1.0	49
269	Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 1635-1642.	1.0	34
270	Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration. <i>Japanese Journal of Ophthalmology</i> , 2011, 55, 123-127.	0.9	6
275	AltersabhÄngige Makuladegeneration. , 2011, , .		3
276	Spectral domain optical coherence tomography for higher precision in the evaluation of vitreoretinal adhesions in exudative age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2011, 95, 1415-1418.	2.1	46
277	Colour photographs for screening in neovascular age-related macular degeneration: are they necessary?. <i>Eye</i> , 2011, 25, 918-921.	1.1	8

#	ARTICLE	IF	CITATIONS
280	Stereotactic Radiosurgery for AMD: A Monte Carlo-Based Assessment of Patient-Specific Tissue Doses. , 2011, 52, 2334.		19
281	SAFETY AND EFFICACY OF A FLEXIBLE DOSING REGIMEN OF RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Evidence-Based Ophthalmology, 2011, 12, 188-189.	0.0	0
282	Pilot Study of Optical Coherence Tomography Measurement of Retinal Blood Flow in Retinal and Optic Nerve Diseases. , 2011, 52, 840.		151
283	Retinal optical coherence tomography: past, present and future perspectives. British Journal of Ophthalmology, 2011, 95, 171-177.	2.1	95
284	Simple Estimation of Clinically Relevant Lesion Volumes Using Spectral Domain Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration. , 2011, 52, 7792.		11
285	Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. British Journal of Ophthalmology, 2011, 95, 386-390.	2.1	48
286	Conversion of Stratus optical coherence tomography (OCT) retinal thickness to Cirrus OCT values in age-related macular degeneration. British Journal of Ophthalmology, 2011, 95, 1552-1554.	2.1	19
287	Stereotactic low-voltage x-ray irradiation for age-related macular degeneration. British Journal of Ophthalmology, 2011, 95, 185-188.	2.1	36
288	Intravitreal Ranibizumab and Bevacizumab in Combination with Full-Fluence Verteporfin Therapy and Dexamethasone for Exudative Age-Related Macular Degeneration. Ophthalmic Research, 2011, 45, 129-134.	1.0	20
289	Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2011, 95, 1555-1559.	2.1	35
290	Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia. Ophthalmologica, 2011, 225, 81-88.	1.0	35
291	Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres. British Journal of Ophthalmology, 2011, 95, 381-385.	2.1	34
292	Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration. Current Vascular Pharmacology, 2011, 9, 629-646.	0.8	39
293	Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography. British Journal of Ophthalmology, 2011, 95, 1424-1426.	2.1	24
294	Role of Thermo-responsiveness and Poly(ethylene glycol) Diacrylate Cross-link Density on Protein Release from Poly(N-isopropylacrylamide) Hydrogels. Journal of Biomaterials Science, Polymer Edition, 2011, 22, 59-75.	1.9	34
295	Administration of Repeat Intravitreal Anti-VEGF Drugs by Retina Specialists in an Injection-only Clinic for Patients with Exudative AMD: Patient Acceptance and Safety. Seminars in Ophthalmology, 2011, 26, 380-386.	0.8	15
296	Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. British Journal of Ophthalmology, 2011, 95, 657-661.	2.1	41
297	Intravitreal Injection Technique. Seminars in Ophthalmology, 2011, 26, 104-113.	0.8	34

#	ARTICLE	IF	CITATIONS
298	Imaging in Neovascular Age-Related Macular Degeneration. <i>Seminars in Ophthalmology</i> , 2011, 26, 225-233.	0.8	40
299	Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. <i>Indian Journal of Ophthalmology</i> , 2011, 59, 191.	0.5	59
300	Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. <i>British Journal of Ophthalmology</i> , 2011, 95, 530-533.	2.1	34
301	Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. <i>Current Opinion in Ophthalmology</i> , 2012, 23, 105-110.	1.3	35
302	Reproducibility of segmentation error correction in age-related macular degeneration: Stratus versus Cirrus OCT. <i>British Journal of Ophthalmology</i> , 2012, 96, 271-275.	2.1	10
303	Association of outer retinal layer morphology with visual acuity in patients with retinal vein occlusion: SCORE Study Report 13. <i>Eye</i> , 2012, 26, 919-924.	1.1	19
304	Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration. <i>Eye</i> , 2012, 26, 389-393.	1.1	9
305	Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period. <i>Eye</i> , 2012, 26, 958-966.	1.1	8
307	Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization. <i>Eye</i> , 2012, 26, 976-982.	1.1	51
308	Optical Coherence Tomography Evaluation in the Multicenter Uveitis Steroid Treatment (MUST) Trial. <i>Ocular Immunology and Inflammation</i> , 2012, 20, 443-447.	1.0	14
309	Ranibizumab for age-related macular degeneration. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 371-381.	1.4	39
310	High-dose ranibizumab therapy for vascularized pigment epithelial detachment. <i>Eye</i> , 2012, 26, 882-885.	1.1	11
311	Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab. <i>Expert Review of Ophthalmology</i> , 2012, 7, 219-225.	0.3	7
312	Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. <i>British Journal of Ophthalmology</i> , 2012, 96, 14-20.	2.1	159
313	Enhanced Depth Imaging Optical Coherence Tomography in Age-related Macular Degeneration. <i>Seminars in Ophthalmology</i> , 2012, 27, 209-212.	0.8	9
314	Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2012, 228, 93-101.	1.0	12
315	Retinal Venular Caliber Predicts Visual Outcome after Intravitreal Ranibizumab Injection Treatments for Neovascular AMD. , 2012, 53, 37.		13
316	Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. <i>British Journal of Ophthalmology</i> , 2012, 96, 21-23.	2.1	125

#	ARTICLE	IF	CITATIONS
317	Älk ÄÄ Doz SonrasÄ Stabilizasyon OranlarÄ AÄÄsÄndan Ranibizumab ve Pegaptanib Sodyum Monoterapilerinin KarÄÄlaÄÄrÄlmasÄ. TÄrk Oftalmoloji Dergisi, 2012, 42, 211-215.	0.4	0
318	Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load. British Journal of Ophthalmology, 2012, 96, 444-447.	2.1	8
319	Choroidal Neovascularization Regression on Fluorescein Angiography after VEGF Blockade. Case Reports in Ophthalmology, 2012, 3, 384-388.	0.3	3
320	RETREATMENT WITH ANTIÄVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY BASED ON CHANGES IN VISUAL ACUITY AFTER INITIAL STABILIZATION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2012, 32, 1471-1479.	1.0	7
321	OVERCOMING SEGMENTATION ERRORS IN MEASUREMENTS OF MACULAR THICKNESS MADE BY SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY. Retina, 2012, 32, 569-580.	1.0	22
322	Sustained Increased Intraocular Pressure Related to Intravitreal Antivascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration. Journal of Glaucoma, 2012, 21, 241-247.	0.8	119
323	MORPHOLOGIC CHARACTERISTICS OF IDIOPATHIC JUXTAFOVEAL TELANGIECTASIA USING SPECTRAL-DOMAIN AND POLARIZATION-SENSITIVE OPTICAL COHERENCE TOMOGRAPHY. Retina, 2012, 32, 256-264.	1.0	8
324	THREE-YEAR FOLLOW-UP OF A PILOT STUDY OF RANIBIZUMAB COMBINED WITH PROTON BEAM IRRADIATION AS TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2012, 32, 956-966.	1.0	15
325	COMBINED FLUORESCEIN ANGIOGRAPHY AND SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY IMAGING OF CLASSIC CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION BEFORE AND AFTER INTRAVITREAL RANIBIZUMAB INJECTIONS. Retina, 2012, 32, 1069-1076.	1.0	17
326	THE EFFECT OF FELLOW EYE VISUAL ACUITY ON VISUAL ACUITY OF STUDY EYES RECEIVING RANIBIZUMAB FOR AGE-RELATED MACULAR DEGENERATION. Retina, 2012, 32, 1243-1249.	1.0	3
327	CHOROIDAL IMAGING USING SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY. Retina, 2012, 32, 865-876.	1.0	123
328	TOPICAL BROMFENAC AS AN ADJUNCTIVE TREATMENT WITH INTRAVITREAL RANIBIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2012, 32, 1804-1810.	1.0	39
329	Effectiveness at 1 Year of Monthly versus Variable-Dosing Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-related Macular Degeneration. Retina, 2012, 32, 293-298.	1.0	13
330	CAUSES OF UNSUCCESSFUL RANIBIZUMAB TREATMENT IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN CLINICAL SETTINGS. Retina, 2012, 32, 1480-1485.	1.0	44
331	INTRAVITREAL RANIBIZUMAB VERSUS BEVACIZUMAB FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2012, 32, 1539-1546.	1.0	73
332	COMBINED INTRAVITREAL RANIBIZUMAB AND PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2012, 32, 1272-1279.	1.0	19
333	Three-Dimensional Segmentation of Fluid-Associated Abnormalities in Retinal OCT: Probability Constrained Graph-Search-Graph-Cut. IEEE Transactions on Medical Imaging, 2012, 31, 1521-1531.	5.4	169
334	Measuring the benefit of 4Ä..years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. British Journal of Ophthalmology, 2012, 96, 1469-1473.	2.1	36

#	ARTICLE	IF	CITATIONS
335	FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2012, 250, 1737-1744.	1.0	22
337	Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases. <i>Biologics in Therapy</i> , 2012, 2, 3.	1.8	17
338	Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: A retrospective study of 58 patients. <i>Journal Francais D'Ophthalmologie</i> , 2012, 35, 661-666.	0.2	11
339	Bevacizumab and ranibizumab for neovascular age-related macular degeneration: a treatment approach based on individual patient needs. <i>Canadian Journal of Ophthalmology</i> , 2012, 47, 165-169.	0.4	9
340	Optical Coherence Tomography Grading Reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2012, 119, 2549-2557.	2.5	59
341	Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration. <i>Canadian Journal of Ophthalmology</i> , 2012, 47, 227-235.	0.4	22
343	Assessment of Differential Pharmacodynamic Effects Using Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration. , 2012, 53, 1152.		20
345	Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 992-1000.	2.5	119
346	Subfoveal Choroidal Thickness after Ranibizumab Therapy for Neovascular Age-related Macular Degeneration: 12-Month Results. <i>Ophthalmology</i> , 2012, 119, 1621-1627.	2.5	152
347	Intravitreal Bevacizumab for Treatment of Subfoveal Idiopathic Choroidal Neovascularization: Results of a 1-Year Prospective Trial. <i>American Journal of Ophthalmology</i> , 2012, 153, 300-306.e1.	1.7	33
348	Bevacizumab for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen: Clinical and Economic Impact. <i>American Journal of Ophthalmology</i> , 2012, 153, 468-473.e1.	1.7	71
349	Fixed-Interval Versus OCT-Guided Variable Dosing of Intravitreal Bevacizumab in the Management of Neovascular Age-Related Macular Degeneration: A 12-Month Randomized Prospective Study. <i>American Journal of Ophthalmology</i> , 2012, 153, 481-489.e1.	1.7	22
350	Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010. <i>American Journal of Ophthalmology</i> , 2012, 153, 209-213.e2.	1.7	277
351	Treatment Patterns for Neovascular Age-Related Macular Degeneration: Analysis of 284 380 Medicare Beneficiaries. <i>American Journal of Ophthalmology</i> , 2012, 153, 1116-1124.e1.	1.7	61
352	One-Year Results of Three Monthly Ranibizumab Injections and As-Needed Reinjections for Polypoidal Choroidal Vasculopathy in Japanese Patients. <i>American Journal of Ophthalmology</i> , 2012, 154, 117-124.e1.	1.7	68
353	Factors Associated With the Response of Age-Related Macular Degeneration to Intravitreal Ranibizumab Treatment. <i>American Journal of Ophthalmology</i> , 2012, 154, 125-136.	1.7	86
354	Improvement of Photoreceptor Integrity and Associated Visual Outcome in Neovascular Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2012, 154, 164-173.e1.	1.7	24
355	Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy. <i>Journal of Cataract and Refractive Surgery</i> , 2012, 38, 677-682.	0.7	34

#	ARTICLE	IF	CITATIONS
356	Ocular Hypertension Following Intravitreal Anti-vascular Endothelial Growth Factor Agents. <i>Drugs and Aging</i> , 2012, 29, 949-956.	1.3	28
357	Retinal Pigment Epithelium Tears in Age-Related Macular Degeneration Treated with Antiangiogenic Drugs: A Controlled Study with Long Follow-Up. <i>Ophthalmologica</i> , 2012, 228, 78-83.	1.0	27
358	Evaluation of Age-related Macular Degeneration With Optical Coherence Tomography. <i>Survey of Ophthalmology</i> , 2012, 57, 389-414.	1.7	230
359	Long-term visual acuity in patients with age-related macular degeneration and persistence of subretinal fluid after treatment with ranibizumab. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2012, 87, 237-246.	0.1	1
360	Pharmakologische Basis der Anti-VEGF Therapie. <i>Spektrum Der Augenheilkunde</i> , 2012, 26, 185-196.	0.2	0
361	<i>CFH</i>, <i>VEGF</i> and <i>HTRA1</i> promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2012, 96, 208-212.	2.1	98
362	The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 361.	0.7	16
363	Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-8.	0.6	11
364	Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-12.	0.6	39
365	Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-11.	0.6	43
366	Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. <i>Clinical Ophthalmology</i> , 2012, 6, 1149.	0.9	21
367	A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2012, 6, 1519.	0.9	13
368	Bruchâ€™s Membrane: The Critical Boundary in Macular Degeneration. , 0, , .		1
369	Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size. <i>Clinical Ophthalmology</i> , 2012, 6, 365.	0.9	6
370	A Novel Technique of Adjusting Segmentation Boundary Layers to Achieve Comparability of Retinal Thickness and Volumes between Spectral Domain and Time Domain Optical Coherence Tomography. , 2012, 53, 5515.		13
371	Optimizing visualization in enhanced depth imaging OCT in healthy subjects and patients with retinal pigment epithelial detachment. <i>Clinical Ophthalmology</i> , 2012, 6, 1915.	0.9	1
372	Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 343.	0.9	15
373	Spectral domain OCT versus time domain OCT in the evaluation of macular features related to wet age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2012, 6, 219.	0.9	21

#	ARTICLE	IF	CITATIONS
374	Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opinion on Pharmacotherapy, 2012, 13, 585-591.	0.9	53
375	The intravitreal injection: Variations in regulations, cost and reimbursement in Europe. Spektrum Der Augenheilkunde, 2012, 26, 2-6.	0.2	8
376	Intravitreal ranibizumab treatment of retinal angiomatous proliferation. Acta Ophthalmologica, 2012, 90, 487-491.	0.6	22
377	Is quantitative spectral-domain superior to time-domain optical coherence tomography (OCT) in eyes with age-related macular degeneration?. Acta Ophthalmologica, 2012, 90, 620-627.	0.6	18
378	Impact of scanning density on spectral domain optical coherence tomography assessments in neovascular age-related macular degeneration. Acta Ophthalmologica, 2012, 90, e274-80.	0.6	20
379	A new fractioning process to decrease the price of ranibizumab. Acta Ophthalmologica, 2012, 90, e645-6.	0.6	0
380	Anti-vascular endothelial growth factor for myopic choroidal neovascularization. Clinical and Experimental Ophthalmology, 2012, 40, e98-e110.	1.3	23
381	Optical coherence tomography for the evaluation of retinal and optic nerve morphology in animal subjects: practical considerations. Veterinary Ophthalmology, 2012, 15, 13-28.	0.6	59
382	Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage. Acta Ophthalmologica, 2013, 91, 274-278.	0.6	24
383	Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmologica, 2013, 91, 42-47.	0.6	50
384	Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 2499-2503.	1.0	20
385	Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 697-704.	1.0	51
386	Drug-induced uveitis. Journal of Ophthalmic Inflammation and Infection, 2013, 3, 43.	1.2	64
387	Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration. Drugs and Aging, 2013, 30, 331-358.	1.3	42
388	A 4-Year Longitudinal Study of 555 Patients Treated with Ranibizumab for Neovascular Age-related Macular Degeneration. Ophthalmology, 2013, 120, 2630-2636.	2.5	99
390	Aflibercept for the Treatment of Age-Related Macular Degeneration. Ophthalmology and Therapy, 2013, 2, 89-98.	1.0	26
391	Comparison of the Effect of Ranibizumab and Verteporfin for Polypoidal Choroidal Vasculopathy: 12-Month LAPTOP Study Results. American Journal of Ophthalmology, 2013, 156, 644-651.e1.	1.7	130
393	Predictive Value of Spectral-Domain Optical Coherence Tomography Features in Assessment of Visual Prognosis in Eyes With Neovascular Age-Related Macular Degeneration Treated With Ranibizumab. American Journal of Ophthalmology, 2013, 155, 720-726.e1.	1.7	38

#	ARTICLE	IF	CITATIONS
394	Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up. <i>Japanese Journal of Ophthalmology</i> , 2013, 57, 301-307.	0.9	10
395	Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up. <i>BMC Ophthalmology</i> , 2013, 13, 10.	0.6	29
396	Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration – evaluation in a clinical setting. <i>BMC Ophthalmology</i> , 2013, 13, 84.	0.6	4
398	Confocal scanning laser ophthalmoscope in the retromode imaging modality in exudative age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 27-34.	1.0	21
399	Inter-observer agreement for spectral- and time-domain optical coherence tomography image grading: a prospective study. <i>International Ophthalmology</i> , 2013, 33, 47-52.	0.6	3
400	Vascular endothelial growth factor and its inhibitor in age-related macular degeneration. <i>Taiwan Journal of Ophthalmology</i> , 2013, 3, 128-133.	0.3	3
401	Fixation stability measurements in patients with neovascular age-related macular degeneration treated with ranibizumab. <i>Canadian Journal of Ophthalmology</i> , 2013, 48, 394-399.	0.4	22
402	Fixation stability as a goal in the treatment of macular disease. <i>Canadian Journal of Ophthalmology</i> , 2013, 48, 364-367.	0.4	20
403	A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2013, 97, 266-271.	2.1	166
404	Retreatment by series of three intravitreal injections of ranibizumab in neovascular age-related macular degeneration: long-term outcomes. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 1901-1907.	1.0	2
405	An update on the pharmacotherapy of neovascular age-related macular degeneration. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1017-1028.	0.9	37
406	Biomaterials in Their Role in Creating New Approaches for the Delivery of Drugs, Proteins, Nucleic Acids, and Mammalian Cells. , 2013, , 677-690.		1
407	Subfoveal Fibrosis in Eyes With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab. <i>American Journal of Ophthalmology</i> , 2013, 156, 116-124.e1.	1.7	74
408	Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2013, 120, 1046-1056.	2.5	432
409	Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks. <i>Acta Ophthalmologica</i> , 2013, 91, e456-e461.	0.6	23
410	Cost and Effectiveness of Therapy for Wet Age-Related Macular Degeneration in Routine Clinical Practice. <i>Ophthalmologica</i> , 2013, 230, 34-42.	1.0	8
411	Pharmacotherapy of Age-Related Macular Degeneration. , 2013, , 1213-1255.		5
412	Four-Year Treatment Results of Neovascular Age-Related Macular Degeneration With Ranibizumab and Causes for Discontinuation of Treatment. <i>American Journal of Ophthalmology</i> , 2013, 155, 89-95.e3.	1.7	85

#	ARTICLE	IF	CITATIONS
413	Anti-VEGF Therapy for AMD: Results and Guidelines. , 2013, , 233-245.		1
414	Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 268-274.	0.3	0
415	Assessment of a Spectral Domain OCT Segmentation Software in a Retrospective Cohort Study of Exudative AMD Patients. <i>Ophthalmologica</i> , 2013, 229, 80-85.	1.0	4
416	Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?. <i>Eye</i> , 2013, 27, 56-64.	1.1	40
417	Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial). <i>Eye</i> , 2013, 27, 959-963.	1.1	22
419	Value of anti-VEGF treatment in choroidal neovascularization associated with autosomal recessive bestrophinopathy. <i>Digital Journal of Ophthalmology: DJO</i> , 2013, 19, 59-63.	0.2	10
420	Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degeneration. <i>Indian Journal of Ophthalmology</i> , 2013, 61, 490.	0.5	6
421	Segmentation error and macular thickness measurements obtained with spectral-domain optical coherence tomography devices in neovascular age-related macular degeneration. <i>Indian Journal of Ophthalmology</i> , 2013, 61, 213.	0.5	17
422	Results of 2â€¦years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy. <i>British Journal of Ophthalmology</i> , 2013, 97, 617-621.	2.1	49
423	CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2013, 33, 1487-1502.	1.0	59
424	VISUAL AND ANATOMICAL OUTCOMES OF INTRAVITREAL AFLIBERCEPT IN EYES WITH PERSISTENT SUBFOVEAL FLUID DESPITE PREVIOUS TREATMENTS WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2013, 33, 1605-1612.	1.0	164
425	INTERLEUKIN 8 PROMOTER POLYMORPHISM PREDICTS THE INITIAL RESPONSE TO BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2013, 33, 1815-1827.	1.0	34
426	A 12-MONTH PROSPECTIVE TRIAL OF INJECT AND EXTEND REGIMEN FOR RANIBIZUMAB TREATMENT OF AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2013, 33, 1351-1358.	1.0	62
427	Characteristics of Patients Who Drop Out From Ranibizumab Therapy. <i>Asia-Pacific Journal of Ophthalmology</i> , 2013, 2, 295-299.	1.3	9
428	ALTERATIONS OF VASCULAR PIGMENT EPITHELIUM DETACHMENTS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION DURING UPLOAD WITH INTRAVITREAL RANIBIZUMAB. <i>Retina</i> , 2013, 33, 1843-1849.	1.0	13
429	An epidemiological study of neovascular age-related macular degeneration in Germany. <i>Current Medical Research and Opinion</i> , 2013, 29, 1391-1397.	0.9	10
430	Treatment of Exudative Age-Related Macular Degeneration with Intravitreal Ranibizumab in Clinical Practice: A 3-Year Follow-Up. <i>Ophthalmologica</i> , 2013, 229, 158-167.	1.0	11
431	What is new in the management of wet age-related macular degeneration?. <i>British Medical Bulletin</i> , 2013, 105, 201-211.	2.7	14

#	ARTICLE	IF	CITATIONS
432	Relationship between Visual Acuity and Spectral Domain Optical Coherence Tomography Retinal Parameters in Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2014, 231, 37-44.	1.0	45
433	Characterization of Neovascular Age-Related Macular Degeneration Patients with Outer Retinal Tubulations. <i>Ophthalmologica</i> , 2013, 229, 147-151.	1.0	31
434	Implementation studies of ranibizumab for neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2013, 91, 1-22.	0.6	7
435	Genetic Association with Response to Intravitreal Ranibizumab for Neovascular Age-Related Macular Degeneration in the Han Chinese Population. <i>Ophthalmologica</i> , 2013, 230, 227-232.	1.0	14
436	Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2013, 97, 1443-1446.	2.1	90
437	Optical coherence tomography – current and future applications. <i>Current Opinion in Ophthalmology</i> , 2013, 24, 213-221.	1.3	440
438	Eye disease in older people. <i>Reviews in Clinical Gerontology</i> , 2013, 23, 234-250.	0.5	2
439	Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2013, 91, e178-83.	0.6	25
440	Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. <i>Acta Ophthalmologica</i> , 2013, 91, 540-546.	0.6	134
441	Long-Term Intraocular Pressure Changes in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab. <i>Ophthalmologica</i> , 2013, 229, 168-172.	1.0	26
442	Lessons learnt inform our approach to new anti-vascular endothelial growth factor treatments for neovascular age-related macular degeneration. <i>Clinical and Experimental Ophthalmology</i> , 2013, 41, 723-726.	1.3	2
443	Automatic detection of subretinal fluid and sub-retinal pigment epithelium fluid in optical coherence tomography images. , 2013, 2013, 7388-91.		9
444	Improving treatment provision of Wet AMD with intravitreal ranibizumab. <i>BMJ Quality Improvement Reports</i> , 2013, 2, u201733.w993.	0.8	2
445	Information Used to Decide on Retreatment of Exudative Age-Related Macular Degeneration with anti-VEGF in Clinical Practice. <i>European Journal of Ophthalmology</i> , 2013, 23, 108-113.	0.7	4
446	RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH ADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY. <i>Retina</i> , 2013, 33, 513-521.	1.0	34
447	FACTORS PREDICTIVE OF OUTCOMES 1 YEAR AFTER 3 MONTHLY RANIBIZUMAB INJECTIONS AND AS-NEEDED REINJECTIONS FOR POLYPOIDAL CHOROIDAL VASCULOPATHY IN JAPANESE PATIENTS. <i>Retina</i> , 2013, 33, 1949-1958.	1.0	20
448	EXPRESSION OF SIRT1 IN CHOROIDAL NEOVASCULAR MEMBRANES. <i>Retina</i> , 2013, 33, 862-866.	1.0	18
449	CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE. <i>Retina</i> , 2013, 33, 474-481.	1.0	182

#	ARTICLE	IF	CITATIONS
451	Clinical applications of optical coherence tomography in the posterior pole: the 2011 José Manuel Espino Lecture ‐ Part II. <i>Clinical Ophthalmology</i> , 2013, 7, 2181.	0.9	19
452	Anti-VEGF-refractory Exudative Age-related Macular Degeneration: Differential Response According to Features on Optical Coherence Tomography. <i>Korean Journal of Ophthalmology: KJO</i> , 2013, 27, 425.	0.5	19
453	Bevacizumab Monotherapy Versus Combined Therapy with Photodynamic Therapy for Occult Choroidal Neovascularization in Age-Related Macular Degeneration. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1554.	0.0	0
454	Bevacizumab inhibits proliferation of choroidal endothelial cells by regulation of the cell cycle. <i>Clinical Ophthalmology</i> , 2013, 7, 321.	0.9	13
455	Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). <i>Clinical Ophthalmology</i> , 2013, 7, 1487.	0.9	45
456	Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2013, 7, 395.	0.9	10
457	Current Smoking Is Associated with a Poor Visual Acuity Improvement after Intravitreal Ranibizumab Therapy in Patients with Exudative Age-Related Macular Degeneration. <i>Journal of Korean Medical Science</i> , 2013, 28, 769.	1.1	17
458	Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients. <i>Clinical Ophthalmology</i> , 2013, 7, 757.	0.9	5
459	Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab. <i>Journal of Ophthalmology</i> , 2013, 2013, 1-7.	0.6	21
460	Grading of Age-Related Macular Degeneration: Comparison between Color Fundus Photography, Fluorescein Angiography, and Spectral Domain Optical Coherence Tomography. <i>Journal of Ophthalmology</i> , 2013, 2013, 1-6.	0.6	58
461	Functional Characterization and Multimodal Imaging of Treatment-NaÃ-ve âQuiescentâ-Choroidal Neovascularization. , 2013, 54, 6886.		128
462	Long-Term Effect of Intravitreal Ranibizumab Injection on Choroidal Neovascularization in Age-Related Macular Degeneration. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1359.	0.0	5
463	The Cellular Origins of the Outer Retinal Bands in Optical Coherence Tomography Images. <i>Investigative Ophthalmology and Visual Science</i> , 2014, 55, 7904-7918.	3.3	141
464	Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis. <i>Clinical Interventions in Aging</i> , 2014, 9, 141.	1.3	15
465	Metamorphopsia and letter recognition. <i>Journal of Vision</i> , 2014, 14, 1-1.	0.1	16
466	One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. <i>Clinical Ophthalmology</i> , 2014, 8, 235.	0.9	26
467	Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity. <i>Korean Journal of Ophthalmology: KJO</i> , 2014, 28, 466.	0.5	2
468	Ranibizumab for the treatment of degenerative ocular conditions. <i>Clinical Ophthalmology</i> , 2014, 8, 1187.	0.9	17

#	ARTICLE	IF	CITATIONS
469	Intravitreal anti-vascular endothelial growth factor treatment for retinal diseases. Journal of the Korean Medical Association, 2014, 57, 614.	0.1	0
470	sA population-based study of macular choroidal neovascularization using optical coherence tomography in Eastern China. Experimental and Therapeutic Medicine, 2014, 8, 371-376.	0.8	0
471	Imaging in Ophthalmology. , 0, , .		2
472	CFH Y402H polymorphism and response to intravitreal Ranibizumab in brazilian patients with neovascular age-related macular degeneration. Revista Do Colegio Brasileiro De Cirurgioes, 2014, 41, 386-392.	0.3	10
473	Ranibizumab Treatment for Choroidal Neovascularization Secondary to Causes Other than Age-Related Macular Degeneration with Good Baseline Visual Acuity. Seminars in Ophthalmology, 2014, 29, 108-113.	0.8	12
474	Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome. Eye, 2014, 28, 1469-1476.	1.1	20
475	Evaluation of clinical and genetic indicators for the early response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics, 2014, 15, 833-843.	0.6	14
476	25th RCOphth Congress, President's Session paper: 25 years of progress in medical retina. Eye, 2014, 28, 1041-1052.	1.1	4
477	Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. British Journal of Ophthalmology, 2014, 98, 1192-1196.	2.1	61
478	Genetic-based prediction of disease traits: prediction is very difficult, especially about the future. Frontiers in Genetics, 2014, 5, 162.	1.1	53
479	Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration. Acta Ophthalmologica, 2014, 92, e697-e698.	0.6	14
480	Ranibizumab Treatment in Age-Related Macular Degeneration: A Meta-Analysis of One-Year Results. Klinische Monatsblätter Fur Augenheilkunde, 2014, 231, 427-431.	0.3	9
481	Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. British Journal of Ophthalmology, 2014, 98, 1629-1635.	2.1	67
482	Fluorescein Angiography and Spectral-Domain Optical Coherence Tomography for Monitoring Anti-VEGF Therapy in Myopic Choroidal Neovascularization. Ophthalmic Research, 2014, 52, 25-31.	1.0	25
483	VEGFGene Polymorphism and Response to Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmic Research, 2014, 51, 1-8.	1.0	18
484	Funduscopy results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain. BMC Ophthalmology, 2014, 14, 138.	0.6	6
485	OPTICAL COHERENCE TOMOGRAPHY-BASED RANIBIZUMAB MONOTHERAPY FOR RETINAL ANGIOMATOUS PROLIFERATION IN KOREAN PATIENTS. Retina, 2014, 34, 2359-2366.	1.0	33
486	Long-term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2014, 25, 158-163.	1.3	30

#	ARTICLE	IF	CITATIONS
487	REASONS FOR DISCONTINUATION OF INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2014, 34, 1774-1778.	1.0	41
488	ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2014, 34, 1531-1538.	1.0	115
489	SENSITIVITY OF FLUID DETECTION IN PATIENTS WITH NEOVASCULAR AMD USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY HIGH-DEFINITION LINE SCANS. <i>Retina</i> , 2014, 34, 1163-1166.	1.0	17
490	INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR CHOROIDAL NEOVASCULARIZATION IN OCULAR HISTOPLASMOSIS. <i>Retinal Cases and Brief Reports</i> , 2014, 8, 24-29.	0.3	11
491	The value of intraoperative optical coherence tomography imaging in vitreoretinal surgery. <i>Current Opinion in Ophthalmology</i> , 2014, 25, 221-227.	1.3	65
492	ENDOPHTHALMITIS ASSOCIATED WITH INTRAVITREAL INJECTIONS. <i>Retina</i> , 2014, 34, 18-23.	1.0	74
493	Age-Related Macular Degeneration. <i>Optometry and Vision Science</i> , 2014, 91, 832-848.	0.6	28
494	Long-term Clinical and Anatomic Outcome of Birdshot Chorioretinopathy. <i>JAMA Ophthalmology</i> , 2014, 132, 57.	1.4	50
495	Phacoemulsification Surgery in Eyes with Neovascular Age-Related Macular Degeneration. <i>ISRN Ophthalmology</i> , 2014, 2014, 1-6.	1.7	21
496	Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2014, 231, 80-85.	1.0	9
497	RESULTS OF INTRAVITREAL RANIBIZUMAB WITH A PRN REGIMEN IN THE TREATMENT OF EXTRAFOVEAL AND JUXTAFOVEAL NEOVASCULAR MEMBRANES IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2014, 34, 860-867.	1.0	8
498	Electrophysiological toxicity testing of <scp>VEGF</scp> Trap&EYE in an isolated perfused vertebrate retina organ culture model. <i>Acta Ophthalmologica</i> , 2014, 92, e305-11.	0.6	13
499	Effects of core vitrectomy in the treatment of age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2014, 92, 465-472.	0.6	9
500	Clinical Utilization of Anti-VEGF Agents and Disease Monitoring in Neovascular Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2014, 157, 825-833.e1.	1.7	77
501	Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 647-655.	1.0	69
502	Comparison of spectral-domain and high-penetration OCT for observing morphologic changes in age-related macular degeneration and polypoidal choroidal vasculopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 3-9.	1.0	11
503	Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 889-897.	1.0	15
504	The Effect of Glutathione as Chain Transfer Agent in PNIPAAm-Based Thermo-responsive Hydrogels for Controlled Release of Proteins. <i>Pharmaceutical Research</i> , 2014, 31, 742-753.	1.7	38

#	ARTICLE	IF	CITATIONS
505	Current Strategies for the Management of Treatment-Resistant Neovascular Age-Related Macular Degeneration. <i>Current Ophthalmology Reports</i> , 2014, 2, 6-13.	0.5	5
506	Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 375-391.	1.3	21
507	A safety audit of the first 10â€™%000 intravitreal ranibizumab injections performed by nurse practitioners. <i>Eye</i> , 2014, 28, 1161-1164.	1.1	34
508	Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. <i>British Journal of Ophthalmology</i> , 2014, 98, 188-194.	2.1	79
509	Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 2181-2192.	2.5	377
510	Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 355-359.	1.0	7
512	Factors influencing the exudation recurrence after cataract surgery in patients previously treated with anti-vascular endothelial growth factor for exudative age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 1573-1579.	1.0	15
513	Megahertz ultra-wide-field swept-source retina optical coherence tomography compared to current existing imaging devices. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 1009-1016.	1.0	54
514	Calculating the predicted retinal thickness from spectral domain and time domain optical coherence tomography â€™ comparison of different methods. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 1491-1499.	1.0	10
515	Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). <i>British Journal of Ophthalmology</i> , 2014, 98, 1144-1167.	2.1	463
516	Impact of Vitreomacular Adhesion on Ranibizumab Mono- and Combination Therapy for Neovascular Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2014, 158, 328-336.e1.	1.7	35
517	Morphologic Parameters Relevant for Visual Outcome During Anti-Angiogenic Therapy of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 1237-1245.	2.5	146
518	Antivascular endothelial growth factor therapies for neovascular age-related macular degeneration: Search for the optimized treatment regimen. <i>Taiwan Journal of Ophthalmology</i> , 2014, 4, 3-8.	0.3	4
519	Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen. <i>British Journal of Ophthalmology</i> , 2014, 98, 1197-1200.	2.1	15
520	Artifacts in optical coherence tomography. <i>Saudi Journal of Ophthalmology</i> , 2014, 28, 81-87.	0.3	31
521	LAPTOP Study: A 24-Month Trial of Verteporfin Versus Ranibizumab for Polypoidal Choroidal Vasculopathy. <i>Ophthalmology</i> , 2014, 121, 1151-1152.	2.5	65
522	Gray Hyper-Reflective Subretinal Exudative Lesions in Exudative Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2014, 158, 354-361.	1.7	37
523	Neovascular Age-Related Macular Degeneration. <i>Developments in Ophthalmology</i> , 2016, 55, 125-136.	0.1	52

#	ARTICLE	IF	CITATIONS
524	Translational public health care perspective: Intravitreal treatment of neovascular age-related macular degeneration has revolutionized clinical ophthalmology. <i>Acta Ophthalmologica</i> , 2015, 93, 103-104.	0.6	6
525	One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages. <i>BMC Ophthalmology</i> , 2015, 15, 182.	0.6	14
526	Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis. <i>International Journal of Retina and Vitreous</i> , 2015, 1, 22.	0.9	6
527	Quantifying metamorphopsia in patients with diabetic macular oedema and other macular abnormalities. <i>Acta Ophthalmologica</i> , 2015, 93, e649-53.	0.6	21
528	INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX). <i>Retina</i> , 2015, 35, 1757-1764.	1.0	23
529	IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. <i>Retina</i> , 2015, 35, 1303-1314.	1.0	54
530	COMPARISON OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY SCAN PATTERNS AND CLINICAL REVIEW STRATEGIES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2015, 35, 1315-1322.	1.0	7
531	INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY. <i>Retina</i> , 2015, 35, 1569-1576.	1.0	101
532	CHANGES OF CHOROIDAL NEOVASCULARIZATION IN INDOCYANINE GREEN ANGIOGRAPHY AFTER INTRAVITREAL RANIBIZUMAB INJECTION. <i>Retina</i> , 2015, 35, 999-1006.	1.0	4
533	REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB. <i>Retina</i> , 2015, 35, 1195-1201.	1.0	58
534	RELATIONSHIP BETWEEN VISUAL PROGNOSIS AND DELAY OF INTRAVITREAL INJECTION OF RANIBIZUMAB WHEN TREATING AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2015, 35, 1331-1338.	1.0	20
535	TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES. <i>Retina</i> , 2015, 35, 1489-1506.	1.0	229
536	VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2015, 35, 1750-1756.	1.0	21
537	Current state of therapeutic strategies with ranibizumab in neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2015, 26, 200-205.	1.3	0
538	Restoration of Outer Retinal Layers After Aflibercept Therapy in Exudative AMD: Prognostic Value. , 2015, 56, 4129.		37
539	Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements. <i>Translational Vision Science and Technology</i> , 2015, 4, 6.	1.1	44
540	Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor. <i>Korean Journal of Ophthalmology: KJO</i> , 2015, 29, 315.	0.5	14
541	Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?. <i>Journal of Clinical Medicine</i> , 2015, 4, 1079-1101.	1.0	26

#	ARTICLE	IF	CITATIONS
542	4 phase-variance optical coherence tomography (pvOCT)Phase-Variance Optical Coherence Tomography. , 2015, , .		0
543	21 Optical Coherence Tomography Diagnosis of Macular Diseases. , 2015, , .		0
544	22 anti-vascular endothelial growth factor (anti-VEGF) therapyOptical Coherence Tomography and Anti-Vascular Endothelial Growth Factor Therapy. , 2015, , .		0
545	Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration. Korean Journal of Ophthalmology: KJO, 2015, 29, 396.	0.5	5
546	Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections. Journal of Ophthalmology, 2015, 2015, 1-5.	0.6	8
547	Blood flow velocity measured using the Retinal Function Imager predicts successful ranibizumab treatment in neovascular age-related macular degeneration: early prospective cohort study. Eye, 2015, 29, 630-636.	1.1	4
548	Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. BMC Ophthalmology, 2015, 15, 40.	0.6	23
549	The Presence of Intra- or Subretinal Fluid during the Loading Phase in the Treatment of Exudative Age-Related Macular Degeneration with Intravitreal Ranibizumab Assessed by Optical Coherence Tomography. Ophthalmologica, 2015, 234, 61-66.	1.0	6
550	Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 579-588.	2.5	57
551	Time to Initial Clinician-Reported Inactivation of Neovascular Age-Related Macular Degeneration Treated Primarily with Ranibizumab. Ophthalmology, 2015, 122, 589-594.e1.	2.5	25
552	Prognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2015, 99, 817-822.	2.1	21
553	Pigment Epithelial Detachment Followed by Retinal Cystoid Degeneration Leads to Vision Loss in Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 822-832.	2.5	170
554	Comparative Safety and Tolerability of Anti-VEGF Therapy in Age-Related Macular Degeneration. Drug Safety, 2015, 38, 279-293.	1.4	20
555	Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab. Japanese Journal of Ophthalmology, 2015, 59, 36-42.	0.9	25
556	Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 221-227.	1.0	27
557	Retinal Pigment Epithelium Tear. Current Ophthalmology Reports, 2015, 3, 26-33.	0.5	6
558	Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye, 2015, 29, 342-349.	1.1	35
559	Clinical characteristics and anti-vascular endothelial growth factor effect of choroidal neovascularization in younger patients in Taiwan. Taiwan Journal of Ophthalmology, 2015, 5, 76-84.	0.3	5

#	ARTICLE	IF	CITATIONS
560	Advances in pharmacotherapy for wet age-related macular degeneration. Expert Opinion on Pharmacotherapy, 2015, 16, 1769-1781.	0.9	27
561	The Effects of Cataract Surgery on Patients With Wet Macular Degeneration. American Journal of Ophthalmology, 2015, 160, 487-492.e1.	1.7	32
562	Quantitative comparison of macular segmentation performance using identical retinal regions across multiple spectral-domain optical coherence tomography instruments. British Journal of Ophthalmology, 2015, 99, 794-800.	2.1	34
564	Changes in Clotting Time, Plasma Fibrinogen Levels, and Blood Viscosity After Administration of Ranibizumab for Treatment of Choroidal Neovascularization. Current Eye Research, 2015, 40, 1166-1171.	0.7	6
565	Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trial. Trials, 2015, 16, 85.	0.7	7
566	Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularizations Associated with Pathologic Myopia: A Prospective Study. Ophthalmologica, 2015, 233, 2-7.	1.0	7
567	Prospective, Randomized Intervention Study Comparing Retinal Pigment Epithelium-Choroid Graft Surgery and Anti-VEGF Therapy in Patients with Exudative Age-Related Macular Degeneration. Ophthalmologica, 2015, 233, 134-145.	1.0	15
568	The diagnostic accuracy of spectral-domain optical coherence tomography for neovascular age-related macular degeneration: a comparison with fundus fluorescein angiography. Eye, 2015, 29, 602-610.	1.1	50
569	Progression of Retinal Pigment Epithelial Atrophy in Antiangiogenic Therapy of Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2015, 159, 1100-1114.e1.	1.7	70
570	Comparison of Eylea® with Lucentis® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis. BMC Ophthalmology, 2015, 15, 109.	0.6	17
571	Intravitreal Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration with Good Baseline Visual Acuity. Ophthalmologica, 2015, 233, 27-34.	1.0	5
572	Oct parameters as predictive factors for the visual outcome after ranibizumab therapy in neovascular age related macular degeneration. Archivos De La Sociedad Espanola De Oftalmologia, 2015, 90, 156-163.	0.1	0
573	Intravitreal Ranibizumab in Daily Clinical Practice for Age-Related Macular Degeneration: Treatment of Exudative Age-Related Macular Degeneration in Real Life. Ophthalmologica, 2015, 234, 26-32.	1.0	9
574	Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study. Ophthalmologica, 2015, 233, 66-73.	1.0	19
575	Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet, The, 2015, 386, 2395-2403.	6.3	154
576	Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up. Ophthalmologica, 2015, 234, 33-39.	1.0	14
577	Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab. Eye, 2015, 29, 1453-1457.	1.1	15
578	Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment. Ophthalmology, 2015, 122, 2303-2310.	2.5	92

#	ARTICLE	IF	CITATIONS
579	Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial. <i>Ophthalmologica</i> , 2015, 234, 40-54.	1.0	37
580	Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing. <i>Current Medical Research and Opinion</i> , 2015, 31, 2031-2042.	0.9	18
581	Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2015, 160, 1014-1023.e2.	1.7	59
583	Rate of vision loss in neovascular age-related macular degeneration explored. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2015, 253, 1859-1865.	1.0	18
584	Treatment Outcomes After 3 Years in Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen. <i>American Journal of Ophthalmology</i> , 2015, 159, 3-8.e1.	1.7	108
585	A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD. <i>Acta Ophthalmologica</i> , 2015, 93, e458-64.	0.6	13
586	Comparison of the 1-year Outcomes of Conbercept Therapy between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy. <i>Chinese Medical Journal</i> , 2016, 129, 2610-2616.	0.9	11
587	The Intraocular Cytokine Profile and Therapeutic Response in Persistent Neovascular Age-Related Macular Degeneration. , 2016, 57, 4144.		64
588	Intravitreal Anti-vascular Endothelial Growth Factor for Treating Polypoidal Choroidal Vasculopathy with Grape-like Polyp Clusters. <i>Korean Journal of Ophthalmology: KJO</i> , 2016, 30, 272.	0.5	3
589	Intravitreal Anti-Vascular Endothelial Growth Factor for Retinal Pigment Epithelial Tear in Retinal Angiomatous Proliferation. <i>Journal of Korean Ophthalmological Society</i> , 2016, 57, 71.	0.0	2
590	Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration. , 2016, 57, OCT14.		64
591	High Dose Intravitreal Bevacizumab for Refractory Pigment Epithelial Detachment in Age-related Macular Degeneration. <i>Korean Journal of Ophthalmology: KJO</i> , 2016, 30, 265.	0.5	9
592	Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2016, 47, 238-244.	0.4	8
593	Tissue thickness calculation in ocular optical coherence tomography. <i>Biomedical Optics Express</i> , 2016, 7, 629.	1.5	38
594	BRIDGE ARCH-SHAPED SEROUS RETINAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2016, 36, 476-482.	1.0	10
595	VOLUMETRIC ASSESSMENT OF THE RESPONSIVENESS OF PIGMENT EPITHELIAL DETACHMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TO INTRAVITREAL BEVACIZUMAB. <i>Retina</i> , 2016, 36, 264-271.	1.0	3
596	EVALUATION OF A TELEMEDICINE MODEL TO FOLLOW UP PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2016, 36, 279-284.	1.0	20
597	ONE-YEAR RESULTS OF ADJUNCTIVE PHOTODYNAMIC THERAPY FOR TYPE 1 NEOVASCULARIZATION ASSOCIATED WITH THICKENED CHOROID. <i>Retina</i> , 2016, 36, 889-895.	1.0	33

#	ARTICLE	IF	CITATIONS
598	CLINICAL TRIAL ENDPOINTS FOR OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2016, 36, S83-S92.	1.0	36
599	Challenges in Applying the Results of Clinical Trials to Clinical Practice. <i>JAMA Ophthalmology</i> , 2016, 134, 928.	1.4	12
600	Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 617-624.	2.5	106
601	Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts. <i>Advances in Therapy</i> , 2016, 33, 715-726.	1.3	11
602	Anti-vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors. <i>Essentials in Ophthalmology</i> , 2016, , 31-65.	0.0	0
603	Method development to quantify Bv8 expression in circulating CD11b+ cells in patients with neovascular age-related macular degeneration (nvAMD) exhibiting Anti-VEGF refractoriness. <i>Experimental Eye Research</i> , 2016, 148, 45-51.	1.2	4
604	Follow-up after surgery for hemorrhagic AMD. <i>Journal Francais D'Ophtalmologie</i> , 2016, 39, 661-667.	0.2	1
605	Self-recognition of recurrences among patients with exudative age-related macular degeneration. <i>Australasian journal of optometry, The</i> , 2016, 99, 56-60.	0.6	0
606	Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 2393-2400.	2.5	47
607	Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 2213-2224.	2.5	43
608	Optical Coherence Tomography Angiography of Mixed Neovascularizations in Age-Related Macular Degeneration. <i>Developments in Ophthalmology</i> , 2016, 56, 62-70.	0.1	12
609	Anti-vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease. <i>Ophthalmology</i> , 2016, 123, S78-S88.	2.5	100
610	Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration. <i>BMC Ophthalmology</i> , 2016, 16, 25.	0.6	4
611	Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT). <i>Ophthalmology</i> , 2016, 123, 1287-1296.	2.5	12
612	Gas-mediated vitreomacular adhesion release with intravitreal ranibizumab injections for exudative age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 1681-1692.	1.0	1
613	Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 2101-2109.	1.0	26
614	Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2016, 168, 1-12.	1.7	92
615	RETROSPECTIVE REVIEW OF LUCENTIS vs TREAT AND EXTEND vs PATTERNS AND OUTCOMES IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2016, 36, 272-278.	1.0	10

#	ARTICLE	IF	CITATIONS
616	Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2016, 134, 182.	1.4	80
617	Ranibizumab for the treatment of wet AMD: a summary of real-world studies. <i>Eye</i> , 2016, 30, 270-286.	1.1	106
618	Treatment for neovascular age related macular degeneration: The state of the art. <i>European Journal of Pharmacology</i> , 2016, 787, 78-83.	1.7	21
619	A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2016, 100, 914-917.	2.1	98
620	Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment. <i>American Journal of Ophthalmology</i> , 2016, 161, 94-103.e1.	1.7	36
621	A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. <i>Progress in Retinal and Eye Research</i> , 2016, 50, 1-24.	7.3	284
622	Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exudative age-related macular degeneration. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 560-565.	1.0	9
623	Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment. <i>Seminars in Ophthalmology</i> , 2017, 32, 309-315.	0.8	8
624	Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , 2017, 1, 314-321.	1.2	79
625	Choroidal Thickness and Visual Prognosis in Type 1 Lesion Due to Neovascular Age-Related Macular Degeneration. <i>European Journal of Ophthalmology</i> , 2017, 27, 196-200.	0.7	5
626	Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy. <i>Ophthalmologica</i> , 2017, 237, 123-127.	1.0	12
627	A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology and Therapy</i> , 2017, 6, 79-92.	1.0	41
628	ROLE OF ADDITIONAL DEXAMETHASONE FOR THE MANAGEMENT OF PERSISTENT OR RECURRENT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDER RANIBIZUMAB TREATMENT. <i>Retina</i> , 2017, 37, 962-970.	1.0	17
629	Imaging of Exudative Age-Related Macular Degeneration: Toward a Shift in the Diagnostic Paradigm?. <i>Retina</i> , 2017, 37, 1625-1629.	1.0	13
630	Neovascular Age-Related Macular Degeneration. , 2017, , 183-203.		0
631	Relationship Between Visual Acuity and Retinal Thickness During Anti-VEGF Vascular Endothelial Growth Factor Therapy for Retinal Diseases. <i>American Journal of Ophthalmology</i> , 2017, 180, 8-17.	1.7	60
632	INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB. <i>Retina</i> , 2017, 37, 1185-1192.	1.0	11
633	LONG-TERM OUTCOMES AND INCIDENCE OF RECURRENCE OF NEOVASCULARIZATION IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2017, 37, 951-961.	1.0	22

#	ARTICLE	IF	CITATIONS
634	Incidence and Timing of the First Recurrence in Neovascular Age-Related Macular Degeneration: Comparison Between Ranibizumab and Aflibercept. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 445-451.	0.6	12
635	Association of Repeated Intravitreal Bevacizumab Injections With Risk for Glaucoma Surgery. <i>JAMA Ophthalmology</i> , 2017, 135, 363.	1.4	53
636	NATURAL COURSE OF PATIENTS DISCONTINUING TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND FACTORS ASSOCIATED WITH VISUAL PROGNOSIS. <i>Retina</i> , 2017, 37, 2254-2261.	1.0	36
637	Submacular hemorrhage and grape-like polyp clusters: factors associated with reactivation of the lesion in polypoidal choroidal vasculopathy. <i>Eye</i> , 2017, 31, 1678-1684.	1.1	14
638	RECURRENCE IN PATIENTS WITH TYPE 3 NEOVASCULARIZATION (RETINAL ANGIOMATOUS PROLIFERATION) AFTER INTRAVITREAL RANIBIZUMAB. <i>Retina</i> , 2017, 37, 1508-1515.	1.0	11
639	Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 2127-2134.	1.0	25
640	24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting. <i>BMC Ophthalmology</i> , 2017, 17, 58.	0.6	23
641	Cystoid Macular Edema. , 2017, , .		0
642	Intravitreal aflibercept in treatment-resistant pigment epithelial detachment. <i>International Ophthalmology</i> , 2017, 37, 531-537.	0.6	5
643	Classification of SD-OCT images using a Deep learning approach. , 2017, , .		58
644	Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept. <i>Journal Francais D'Ophtalmologie</i> , 2017, 40, 832-838.	0.2	13
645	Ten-Year Follow-Up after Bilateral Submacular Neovascular Membrane Removal in a Case of Autosomal Recessive Bestrophinopathy. <i>Case Reports in Ophthalmology</i> , 2017, 8, 265-270.	0.3	4
647	Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel. <i>Asia-Pacific Journal of Ophthalmology</i> , 2017, 6, 296-302.	1.3	20
648	Efficacy of Three Aflibercept Injections for Neovascular Age-related Macular Degeneration Showing Limited Response to Ranibizumab. <i>Journal of Korean Ophthalmological Society</i> , 2017, 58, 62.	0.0	4
649	Recent developments in age-related macular degeneration: a review. <i>Clinical Interventions in Aging</i> , 2017, Volume 12, 1313-1330.	1.3	285
650	The ecosystem that powered the translation of OCT from fundamental research to clinical and commercial impact [Invited]. <i>Biomedical Optics Express</i> , 2017, 8, 1638.	1.5	102
651	Safety and Effectiveness of Cataract Surgery with Simultaneous Intravitreal Anti-VEGF in Patients with Previously Treated Exudative Age-Related Macular Degeneration. <i>Acta Medica Portuguesa</i> , 2017, 30, 127-133.	0.2	6
652	Robust total retina thickness segmentation in optical coherence tomography images using convolutional neural networks. <i>Biomedical Optics Express</i> , 2017, 8, 3292.	1.5	106

#	ARTICLE	IF	CITATIONS
653	Intrinsically Photosensitive Retinal Ganglion Cell Function, Sleep Efficiency and Depression in Advanced Age-Related Macular Degeneration. , 2017, 58, 990.		40
654	Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab. BMC Ophthalmology, 2017, 17, 147.	0.6	12
655	Fourteen Anti-vascular Endothelial Growth Factor Injections for Age-related Macular Degeneration: Ending Period and Clinical Outcome. Journal of Korean Ophthalmological Society, 2017, 58, 1042.	0.0	2
656	Neovascular (Wet) Age-Related Macular Degeneration. , 2017, , 89-116.		3
657	Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial. Clinical Ophthalmology, 2017, Volume 11, 223-231.	0.9	13
658	Testing the clinical value of multifocal electroretinography and microperimetry and the effects of intravitreal therapy with ranibizumab on macular function in the course of wet age-related macular degeneration: a 1-year prospective study. Clinical Ophthalmology, 2017, Volume 11, 621-629.	0.9	7
659	Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome. Korean Journal of Ophthalmology: KJO, 2017, 31, 240.	0.5	4
660	Comparison of Neovascular Lesion Area Measurements From Different Swept-Source OCT Angiographic Scan Patterns in Age-Related Macular Degeneration. , 2017, 58, 5098.		18
661	Anatomical Characteristics of End-stage Exudative Age-related Macular Degeneration Refractory to Intravitreal Anti-vascular Endothelial Growth Factor Injection. Journal of Korean Ophthalmological Society, 2017, 58, 1145.	0.0	0
663	Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. Survey of Ophthalmology, 2018, 63, 638-645.	1.7	41
664	Development of facile drug delivery platform of ranibizumab fabricated PLGA-PEGylated magnetic nanoparticles for age-related macular degeneration therapy. Journal of Photochemistry and Photobiology B: Biology, 2018, 183, 133-136.	1.7	24
665	Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration. American Journal of Ophthalmology, 2018, 191, 135-139.	1.7	33
666	Evolution of Intravitreal Therapy for Retinal Diseasesâ€”From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture. American Journal of Ophthalmology, 2018, 191, xli-lviii.	1.7	32
667	Comparison of macular parameters after femtosecond laserâ€”assisted and conventional cataract surgery in age-related macular degeneration. Journal of Cataract and Refractive Surgery, 2018, 44, 23-27.	0.7	6
668	Differential diagnosis of neovascular age-related macular degeneration. Spektrum Der Augenheilkunde, 2018, 32, 12-17.	0.2	1
669	Hyperpigmented spots after treatment for submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 469-477.	1.0	9
670	Long-Term Outcomes in Patients with Neovascular Age-Related Macular Degeneration Who Maintain Dry Macula after Three Monthly Ranibizumab Injections. Seminars in Ophthalmology, 2018, 33, 371-376.	0.8	5
671	THICKNESS OF THE MACULA, RETINAL NERVE FIBER LAYER, AND GANGLION CELLâ€”INNER PLEXIFORM LAYER IN THE AGE-RELATED MACULAR DEGENERATION. Retina, 2018, 38, 253-262.	1.0	17

#	ARTICLE	IF	CITATIONS
672	ANGIOPOIETIN-LIKE 4 CORRELATES WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB INJECTIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2018, 38, 523-530.	1.0	14
673	Optical Biometry Derived Axial Length Measurements Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema. <i>Seminars in Ophthalmology</i> , 2018, 33, 488-491.	0.8	5
675	Effect of cataract surgery in patients with neovascular age-related macular degeneration: further evidence from disciform scars. <i>International Ophthalmology</i> , 2018, 38, 459-467.	0.6	4
676	POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPICAL ANTIBIOTIC PROPHYLAXIS. <i>Retina</i> , 2018, 38, 01-11.	1.0	37
677	Features of optical coherence tomography predictive of choroidal neovascularisation treatment response in pathological myopia in association with fluorescein angiography. <i>British Journal of Ophthalmology</i> , 2018, 102, 238-242.	2.1	13
678	MORPHOLOGIC FEATURES ASSOCIATED WITH FIBROTIC SCARRING AFTER ANTI-VEGF VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN POLYPOIDAL CHOROIDAL VASCULOPATHY. <i>Retina</i> , 2018, 38, 2168-2176.	1.0	9
679	Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry. <i>Ophthalmology</i> , 2018, 125, 522-528.	2.5	111
680	Estimating Public and Patient Savings From Basic Research: A Study of Optical Coherence Tomography in Managing Antiangiogenic Therapy. <i>American Journal of Ophthalmology</i> , 2018, 185, 115-122.	1.7	35
681	Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. <i>British Journal of Ophthalmology</i> , 2018, 102, 460-464.	2.1	34
682	Long-term Recurrence in Neovascular Age-related Macular Degeneration or Polypoidal Choroidal Vasculopathy without First Year Recurrence. <i>Journal of Korean Ophthalmological Society</i> , 2018, 59, 908.	0.0	0
683	Long-term Treatment Outcome of Intravitreal Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy. <i>Journal of Korean Ophthalmological Society</i> , 2018, 59, 238.	0.0	2
684	Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey. <i>International Journal of Ophthalmology</i> , 2018, 11, 267-273.	0.5	4
685	Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPIn Therapeutic) in Neovascular Age-Related Macular Degeneration. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2018, 34, 700-709.	0.6	59
686	Facile synthetic Photoluminescent Graphene Quantum dots encapsulated β -cyclodextrin drug carrier system for the management of macular degeneration: Detailed analytical and biological investigations. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2018, 189, 244-249.	1.7	17
687	Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 2383-2391.	0.9	10
688	Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 593-600.	0.9	11
689	Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen. <i>Journal of Ophthalmology</i> , 2018, 2018, 1-7.	0.6	25
690	Effect of patch size and network architecture on a convolutional neural network approach for automatic segmentation of OCT retinal layers. <i>Biomedical Optics Express</i> , 2018, 9, 3049.	1.5	91

#	ARTICLE	IF	CITATIONS
691	14 Age-Related Macular Degeneration. , 2018, , .		0
692	Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, S3-S15.	0.5	89
693	Volume-Rendered Projection-Resolved OCT Angiography: 3D Lesion Complexity Is Associated With Therapy Response in Wet Age-Related Macular Degeneration. , 2018, 59, 1944.		20
695	The Treat-and-Extend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis. <i>American Journal of Ophthalmology</i> , 2018, 192, 184-197.	1.7	57
696	Retinal volume change is a reliable OCT biomarker for disease activity in neovascular AMD. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 1623-1629.	1.0	13
697	Spectral Domain Optical Coherence Tomography Allows the Unification of Clinical Decision Making for the Evaluation of Choroidal Neovascularization Activity. <i>Ophthalmologica</i> , 2019, 241, 32-37.	1.0	4
698	Optical Coherence Tomography-Based Deep-Learning Models for Classifying Normal and Age-Related Macular Degeneration and Exudative and Non-Exudative Age-Related Macular Degeneration Changes. <i>Ophthalmology and Therapy</i> , 2019, 8, 527-539.	1.0	70
699	Influence of Axial Length on Recurrence of Wet Age-related Macular Degeneration after Initial Treatment. <i>Journal of Korean Ophthalmological Society</i> , 2019, 60, 47.	0.0	0
700	Optical coherence tomography angiography characteristics of choroidal neovascularization requiring varied dosing frequencies in treat-and-extend management: An analysis of the AVATAR study. <i>PLoS ONE</i> , 2019, 14, e0218889.	1.1	14
701	Long-term Treatment Outcomes of Intravitreal Bevacizumab Treatment for Myopic Choroidal Neovascularization. <i>Journal of Korean Ophthalmological Society</i> , 2019, 60, 547.	0.0	2
702	Segmentation of Symptomatic Exudate-Associated Derangements in 3D OCT Images. <i>Biological and Medical Physics Series</i> , 2019, , 345-365.	0.3	0
703	Retinal Optical Coherence Tomography Image Analysis. <i>Biological and Medical Physics Series</i> , 2019, , .	0.3	3
704	Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 2559-2569.	1.0	23
705	Automatic choroidal segmentation in OCT images using supervised deep learning methods. <i>Scientific Reports</i> , 2019, 9, 13298.	1.6	82
706	Increase in the Population of Patients with Neovascular Age-Related Macular Degeneration Who Underwent Long-Term Active Treatment. <i>Scientific Reports</i> , 2019, 9, 13264.	1.6	17
707	LONG-TERM VISUAL CHANGES IN INITIALLY STRONGER FELLOW EYES IN PATIENTS WITH UNILATERAL TYPE 3 NEOVASCULARIZATION. <i>Retina</i> , 2019, 39, 1672-1681.	1.0	8
708	Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study. <i>Scientific Reports</i> , 2019, 9, 529.	1.6	46
710	OPTICAL COHERENCE TOMOGRAPHY, FLUORESCEIN ANGIOGRAPHY, AND DIAGNOSIS OF CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2019, 39, 1664-1671.	1.0	23

#	ARTICLE	IF	CITATIONS
711	Best Clinical Practice for Age-Related Macular Degeneration Imaging. <i>Journal of Vitreoretinal Diseases</i> , 2019, 3, 167-171.	0.2	4
712	Lessons Learned From Avastin and OCT—The Great, the Good, the Bad, and the Ugly: The LXXV Edward Jackson Memorial Lecture. <i>American Journal of Ophthalmology</i> , 2019, 204, 26-45.	1.7	10
713	Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease. <i>Ophthalmology</i> , 2019, 126, 841-848.	2.5	61
714	Feasibility of support vector machine learning in age-related macular degeneration using small sample yielding sparse optical coherence tomography data. <i>Acta Ophthalmologica</i> , 2019, 97, e719-e728.	0.6	10
715	Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 1183-1189.	1.0	9
716	Association of imaging factors derived from convolutional neural network with visual outcomes in age-related macular degeneration and polypoidal choroidal vasculopathy. <i>Scientific Reports</i> , 2019, 9, 19857.	1.6	2
717	Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. <i>BMJ Open Ophthalmology</i> , 2019, 4, e000398.	0.8	85
718	Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies. <i>British Journal of Ophthalmology</i> , 2019, 104, bjophthalmol-2019-315021.	2.1	4
719	Deep Learning Classification Models Built with Two-step Transfer Learning for Age Related Macular Degeneration Diagnosis. , 2019, 2019, 2049-2052.		10
720	37 Age-related macular degeneration (AMD)nonexudativeNonexudative Age-Related Macular Degeneration. , 2019, , .		0
721	Treat-and-extend regimens with anti-vascular endothelial growth factor agents in age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2019, 14, 287-307.	0.3	2
722	Harnessing the Power of Optical Microscopic and Macroscopic Imaging for Natural Products as Cancer Therapeutics. <i>Frontiers in Pharmacology</i> , 2019, 10, 1438.	1.6	1
723	Artificial intelligence-based decision-making for age-related macular degeneration. <i>Theranostics</i> , 2019, 9, 232-245.	4.6	116
724	Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?. <i>Ophthalmology Retina</i> , 2020, 4, 141-147.	1.2	11
725	Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2020, 98, 132-138.	0.6	30
726	Age-Related Macular Degeneration Preferred Practice Pattern®. <i>Ophthalmology</i> , 2020, 127, P1-P65.	2.5	167
727	Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 107-116.	1.0	13
728	INFLUENCE OF FELLOW-EYE EXAMINATION INTERVAL ON VISUAL ACUITY AT FELLOW-EYE NEOVASCULARIZATION IN UNILATERAL TYPE 3 NEOVASCULARIZATION. <i>Retina</i> , 2020, 40, 1255-1261.	1.0	5

#	ARTICLE	IF	CITATIONS
729	Results of Switching from Pro Re Nata to Treat-and-Extend Regimen in Treatment of Patients with Type 3 Neovascularization. <i>Seminars in Ophthalmology</i> , 2020, 35, 33-40.	0.8	11
730	Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study. <i>Ophthalmology Retina</i> , 2020, 4, 1138-1145.	1.2	20
731	Retinal Fluids Segmentation Using Volumetric Deep Neural Networks on Optical Coherence Tomography Scans. , 2020, , .		0
732	Management of Fluid in Neovascular Age-related Macular Degeneration: To Mop it, to Dab it, or to Leave it?. <i>Retina</i> , 2020, 40, 1451-1455.	1.0	11
733	Performance Evaluation Of Convolutions And Atrous Convolutions In Deep Networks For Retinal Disease Segmentation On Optical Coherence Tomography Volumes. , 2020, 2020, 1863-1866.		3
734	Long-Term Outcomes of Switching from Fixed-Dose to As-Needed Regimen for Treating Submacular Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2637.	1.0	0
735	Fibrovascular pigment epithelial detachment in eyes with subretinal hemorrhage secondary to neovascular AMD or PCV: a morphologic predictor associated with poor treatment outcomes. <i>Scientific Reports</i> , 2020, 10, 14943.	1.6	9
736	An Intelligent Optical Coherence Tomography-based System for Pathological Retinal Cases Identification and Urgent Referrals. <i>Translational Vision Science and Technology</i> , 2020, 9, 46.	1.1	9
737	Treat and extend versus fixed regimen in neovascular age related macular degeneration: A systematic review and meta-analysis. <i>European Journal of Ophthalmology</i> , 2021, 31, 2496-2504.	0.7	10
738	Long-term switching between ranibizumab and aflibercept in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 1677-1685.	1.0	5
739	Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA. <i>British Journal of Ophthalmology</i> , 2020, 104, 672-677.	2.1	14
740	Management and Outcomes for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2020, 127, 1179-1188.	2.5	29
741	Deep learning architectures analysis for age-related macular degeneration segmentation on optical coherence tomography scans. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 195, 105566.	2.6	26
742	Decreased Periodicity of Reactivation Interval in Neovascular Age-Related Macular Degeneration in Patients with a Late First Reactivation After Initial Treatment. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2020, 36, 703-710.	0.6	1
743	Three-Year Outcomes of Patients with Neovascular Age-Related Macular Degeneration Treated with Aflibercept under the National Health Insurance Program in Taiwan. <i>Journal of Ophthalmology</i> , 2020, 1-8.	0.6	5
744	<p>Consolidation of Imaging Modalities Utilizing Digitally Assisted Visualization Systems: The Development of a Surgical Information Handling Cockpit</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 557-569.	0.9	7
745	The relationship between pigment epithelial detachment and visual outcome in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. <i>Eye</i> , 2020, 34, 2257-2263.	1.1	9
746	Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-7.	0.6	3

#	ARTICLE	IF	CITATIONS
747	One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study. <i>Ophthalmologica</i> , 2020, 243, 255-262.	1.0	18
748	A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration. <i>BMC Ophthalmology</i> , 2020, 20, 21.	0.6	1
749	Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study. <i>BMC Ophthalmology</i> , 2020, 20, 18.	0.6	8
750	One-year outcomes of the Polish treatment program for the wet form of age-related macular degeneration using intravitreal therapy. <i>European Journal of Ophthalmology</i> , 2020, 30, 586-594.	0.7	5
751	Long-Term Treatment Outcomes in Type 3 Neovascularization: Focus on the Difference in Outcomes between Geographic Atrophy and Fibrotic Scarring. <i>Journal of Clinical Medicine</i> , 2020, 9, 1145.	1.0	11
752	Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration. <i>Survey of Ophthalmology</i> , 2021, 66, 68-97.	1.7	15
753	Retinal pigment epithelial characteristics in eyes with neovascular age-related macular degeneration. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 123-130.	1.0	3
754	Quantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration Using Deep Learning. <i>Ophthalmology</i> , 2021, 128, 693-705.	2.5	64
755	Clinical characteristics of super stable polypoidal choroidal vasculopathy after initial remission with anti-VEGF monotherapy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 837-846.	1.0	4
756	Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naïve neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 1463-1470.	1.0	10
757	Strongest Correlation Between Contrast Sensitivity and Morphological Characteristics in Bilateral nAMD. <i>Frontiers in Medicine</i> , 2020, 7, 622877.	1.2	7
758	The promising retinal optical coherence tomography biomarkers in common macular diseases: A brief summary of the literature. <i>Alpha Psychiatry</i> ; 2021, , .	0.0	0
759	Comparison of the effects of anti-vascular endothelial growth factor treatments on pigment epithelial detachment in age-related macular degeneration. <i>International Ophthalmology</i> , 2021, 41, 1363-1372.	0.6	2
760	Quantitative Analysis of the Activity in Choroidal Neovascularizations after a Single Anti-VEGF Injection: OCT Versus OCT Angiography. <i>Seminars in Ophthalmology</i> , 2021, 36, 573-581.	0.8	1
761	ASSESSMENT OF EARLY CHANGES IN SPECTRAL DOMAIN-OPTICAL COHERENCE TOMOGRAPHY AFTER INITIATION OF TREATMENT WITH INTRAVITREAL AFLIBERCEPT (EYLEA) OVER A 12-WEEK PERIOD FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2021, 41, 588-594.	1.0	1
762	Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the InEye study. <i>Acta Ophthalmologica</i> , 2021, 99, 861-870.	0.6	21
763	Safety and efficacy of Razumab [®] , (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study. <i>International Journal of Retina and Vitreous</i> , 2021, 7, 24.	0.9	9
764	PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections. <i>Journal of Ophthalmic and Vision Research</i> , 2021, 16, 178-186.	0.7	3

#	ARTICLE	IF	CITATIONS
765	One year outcomes of treat and extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy. <i>European Journal of Ophthalmology</i> , 2021, 31, 2868-2875.	0.7	4
766	RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2021, 41, 1579-1586.	1.0	24
767	Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2758.	1.0	42
768	Intravitreal anti-VEGF use in France: a cross-sectional and longitudinal Nationwide observational study. <i>Acta Ophthalmologica</i> , 2022, 100, .	0.6	10
769	One-year Outcomes of a Treat-and-extend of Ranibizumab for Naive Exudative Age-related Macular Degeneration: Retrospective Analysis. <i>Journal of Korean Ophthalmological Society</i> , 2021, 62, 939-947.	0.0	0
770	Management of neovascular age-related macular degeneration: Taiwan expert consensus. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 2061-2071.	0.8	7
771	Proportion and Reasons for Ineligibility to Re-register for Extended Health Insurance in Neovascular Age-related Macular Degeneration. <i>Journal of Korean Ophthalmological Society</i> , 2021, 62, 948-956.	0.0	0
772	Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 3351-3367.	0.9	15
773	Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. <i>Japanese Journal of Ophthalmology</i> , 2021, 65, 741-760.	0.9	7
774	SINGLE INJECTION RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2021, 41, 1901-1910.	1.0	4
775	Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy. <i>British Journal of Ophthalmology</i> , 2023, 107, 399-405.	2.1	11
776	Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. <i>Pharmaceutics</i> , 2021, 13, 1491.	2.0	4
777	Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4153.	1.0	17
778	ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR DOSING AND EXPECTED ACUITY OUTCOME AT 1 YEAR. <i>Retina</i> , 2021, 41, 1153-1163.	1.0	7
779	Deep learning for ophthalmology using optical coherence tomography. , 2021, , 239-269.		2
780	Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2021, 139, 68.	1.4	50
781	Difference in treatment burden of neovascular age-related macular degeneration among different types of neovascularization. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 1821-1830.	1.0	9
782	Fundus Imaging of Age-Related Macular Degeneration. , 2011, , 39-64.		1

#	ARTICLE	IF	CITATIONS
783	Automatic Retinal and Choroidal Boundary Segmentation in OCT Images Using Patch-Based Supervised Machine Learning Methods. Lecture Notes in Computer Science, 2019, , 215-228.	1.0	7
784	Principles and Applications of Modern Optical Coherence Tomography. , 2009, , 67-83.		1
785	INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH OR WITHOUT PRIOR TREATMENT WITH PHOTODYNAMIC THERAPY. Retina, 2010, 30, 85-92.	1.0	15
786	Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes. Medical Science Monitor, 2011, 17, CR485-CR490.	0.5	7
787	Influence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degeneration. Medical Science Monitor, 2014, 20, 875-883.	0.5	6
788	Flicker-induced changes in retinal blood flow assessed by Doppler optical coherence tomography. Biomedical Optics Express, 2011, 2, 1852-60.	1.5	22
789	Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study. PLoS ONE, 2017, 12, e0176100.	1.1	18
790	Incidence and risk factors of massive subretinal hemorrhage in retinal angiomatous proliferation. PLoS ONE, 2017, 12, e0186272.	1.1	16
791	Six-year outcomes in neovascular age-related macular degeneration with ranibizumab. International Journal of Ophthalmology, 2017, 10, 81-90.	0.5	18
792	Adaptive optics scanning laser ophthalmoscopy in fundus imaging, a review and update. International Journal of Ophthalmology, 2017, 10, 1751-1758.	0.5	16
793	Anti-VEGF Treatment and Response in Age-related Macular Degeneration: Disease's Susceptibility, Pharmacogenetics and Pharmacokinetics. Current Medicinal Chemistry, 2020, 27, 549-569.	1.2	12
794	Common Variant in VEGFA and Response to Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration. Current Molecular Medicine, 2013, 13, 929-934.	0.6	36
795	Clinical Risk Factors for Poor Anatomic Response to Ranibizumab in Neovascular Age-Related Macular Degeneration. Open Ophthalmology Journal, 2014, 8, 3-6.	0.1	9
796	Population-Based Age Group Specific Annual Incidence Rates of Symptomatic Age-Related Macular Degeneration. Open Ophthalmology Journal, 2014, 8, 95-100.	0.1	2
797	The Treatment of Wet Age-Related Macular Degeneration. Deutsches Ärztblatt International, 2009, 106, 312-7.	0.6	19
798	Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database. Journal of Health Economics and Outcomes Research, 2014, 2, 41-52.	0.6	4
800	Treatment of Neovascular Age-Related Macular Degeneration with Pegaptanib and Boosting with Bevacizumab or Ranibizumab as Needed. Ophthalmic Surgery Lasers and Imaging Retina, 2008, 39, 294-298.	0.4	7
801	Photodynamic Therapy With and Without Adjunctive Intravitreal Triamcinolone Acetonide: A Retrospective Comparative Study. Ophthalmic Surgery Lasers and Imaging Retina, 2009, 40, 561-569.	0.4	8

#	ARTICLE	IF	CITATIONS
802	Ranibizumab for Exudative Age-Related Macular Degeneration in Eyes Previously Treated With Alternative Vascular Endothelial Growth Factor Inhibitors. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 182-189.	0.4	18
803	Repeatability of Retinal Thickness Measurements Between Spectral-Domain and Time-Domain Optical Coherence Tomography Images in Macular Disease. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, S34-41.	0.4	18
804	Reproducibility of Macular Thickness Measurement Among Five OCT Instruments: Effects of Image Resolution, Image Registration, and Eye Tracking. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2012, 43, 97-108.	0.4	30
805	Ocular Hypertension and Intraocular Pressure Asymmetry After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2013, 44, 460-464.	0.4	34
806	Clinical Monitoring of Patients With Age-Related Macular Degeneration Treated With Intravitreal Bevacizumab or Ranibizumab. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2014, 45, 285-291.	0.4	11
807	Ultrahigh-Speed Swept-Source OCT Angiography in Exudative AMD. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2014, 45, 496-505.	0.4	206
808	Improved Repeatability of Retinal Thickness Measurements Using Line-Scan Ophthalmoscope Image-Based Retinal Tracking. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2015, 46, 310-314.	0.4	6
809	Vitreous Incarceration After Ranibizumab Injection: An Ultrasound Biomicroscopy Study. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2015, 46, 471-474.	0.4	3
810	Relationship Between Subretinal Hyperreflective Material Reflectivity and Volume in Patients With Neovascular Age-Related Macular Degeneration Following Anti-Vascular Endothelial Growth Factor Treatment. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2015, 46, 523-530.	0.4	37
811	Serous Index of Pigment Epithelial Detachments in Neovascular Age-Related Macular Degeneration Predicts Response to Anti-Vascular Endothelial Growth Factor Treatment. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2015, 46, 724-727.	0.4	3
812	SLO-Microperimetry in Wet Age-Related Macular Degeneration During Anti-VEGF Therapy. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2015, 46, 824-830.	0.4	5
813	Intraoperative Drainage of a Bullous Serous Pigment Epithelial Detachment. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2019, 50, 510-513.	0.4	1
814	Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats. <i>International Journal of Ophthalmology</i> , 2014, 7, 1-7.	0.5	61
815	Bilateral same-session intravitreal injections of anti-vascular endothelial growth factors. <i>International Journal of Ophthalmology</i> , 2014, 7, 1017-21.	0.5	15
816	Management of neovascular Age-related macular degeneration: A review on landmark randomized controlled trials. <i>Middle East African Journal of Ophthalmology</i> , 2016, 23, 27.	0.5	24
817	Quantitative physiological measurements to evaluate the response of anti-vascular endothelial growth factor treatment in patients with neovascular diseases. <i>Indian Journal of Ophthalmology</i> , 2017, 65, 559.	0.5	4
818	Optical coherence tomography: A guide to interpretation of common macular diseases. <i>Indian Journal of Ophthalmology</i> , 2018, 66, 20.	0.5	83
819	Evaluation of Microcollimated Pars Plana External Beam Radiation in the Porcine Eye. <i>Journal of Clinical & Experimental Ophthalmology</i> , 2011, 02, .	0.1	4

#	ARTICLE	IF	CITATIONS
820	Prognostic Factors for Long Term Visual Acuity Outcome after Ranibizumab Therapy in Patients with Neovascular Age-Related Macular Degeneration. Journal of Clinical & Experimental Ophthalmology, 2013, 04, .	0.1	5
822	One-Year Results of Aflibercept in Vascularized Pigment Epithelium Detachment due to Neovascular AMD: A Prospective Study. European Journal of Ophthalmology, 2017, 27, 74-79.	0.7	9
823	Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2012, 156, 359-364.	0.2	1
824	Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept. Frontiers in Immunology, 2021, 12, 738521.	2.2	8
831	Pacientes no respondedores a anti-VEGF. , 2010, , 81-93.		1
832	Quantitative analysis of the Stratus optical coherence tomography fast macular thickness map reports. Indian Journal of Ophthalmology, 2010, 58, 131.	0.5	2
833	Fluorescein Angiography. Essentials in Ophthalmology, 2010, , 19-26.	0.0	0
834	Seguridad sistÃ©mica del tratamiento anti-VEGF. , 2010, , 155-161.		0
835	Principales ensayos clÃ©nicos con fÃ¡rmacos anti-VEGF en la DMAE exudativa. , 2010, , 7-14.		0
836	Pautas de seguimiento y retratamiento en pacientes con degeneraciÃ³n macular tratados con ranibizumab (Lucentis®). , 2010, , 15-23.		0
837	TomografÃ­a de coherencia Ã³ptica en el seguimiento del tratamiento anti-VEGF. , 2010, , 39-48.		0
839	Anti-VEGF-Therapie der AMD: Ergebnisse und Leitlinien. , 2011, , 237-251.		0
840	Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment. Journal of Clinical & Experimental Ophthalmology, 2012, 02, .	0.1	0
841	Combination Treatment Strategies in Neovascular AMD. , 2012, , 501-515.		0
842	Prise en charge de la DMLA exudative en 2013. Bulletin De L'Academie Nationale De Medecine, 2013, 197, 1339-1346.	0.0	0
843	Anti-VEGF Therapy - Managing Challenging Case Scenarios. Delhi Journal of Ophthalmology, 2014, 25, 129-136.	0.0	1
844	Facoemulsificaci&ocute;n en Ojos con Degeneraci&ocute;n Macular Neovascular Relacionada con la Edad. Highlights of Ophthalmology, 2015, 43, 12-16.	0.0	0
845	Facoemulsificaci&ocute;n en Ojos con Degeneraci&ocute;n Macular Relacionada con la Edad. Highlights of Vitreoretina, 2015, 8, 2-6.	0.0	0

#	ARTICLE	IF	CITATIONS
846	Phacoemulsification Surgery in Eyes with Neovascular Age-Related Macular Degeneration. Highlights of Ophthalmology, 2015, 43, 12-16.	0.0	0
848	Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinal Angiomatous Proliferation: A Review of the Literature and Therapeutic Considerations. Journal of Retina, 2016, 1, 11-22.	0.1	1
849	Factors Associated With Poor Response to Aflibercept After Switching From Ranibizumab or Bevacizumab in Neovascular Age-related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2016, 47, 458-465.	0.4	3
850	Management of Macular Edema in Vitreo-Maculopathies. , 2017, , 91-120.		0
851	Inhibition of proliferation of retinal vascular endothelial cells more effectively than choroidal vascular endothelial cell proliferation by bevacizumab. International Journal of Ophthalmology, 2017, 10, 15-22.	0.5	2
852	Aspectos clínicos relevantes en el diagnóstico de las oclusiones venosas retinianas: revisión. Ciencia Y Tecnología Para La Salud Visual Y Ocular, 2017, 15, 91.	0.1	3
853	Two-year Outcomes after Intravitreal Anti-vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy Patients with Good Initial Visual Acuity. Journal of Retina, 2017, 2, 12-20.	0.1	0
854	One-year Treatment Outcome of Intravitreal Aflibercept for Neovascular Age-related Macular Degeneration with Good Initial Visual Acuity. Journal of Retina, 2017, 2, 21-26.	0.1	0
855	Whither (or Wither) Adherence to Retina Trial Protocols in Clinical Practice?. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 692-698.	0.4	2
857	Image-guided intraocular injection using multimodality optical coherence tomography and fluorescence confocal scanning laser ophthalmoscopy in rodent ophthalmological models. , 2018, , .		0
858	Detection and registration of vessels for longitudinal 3D retinal OCT images using SURF. , 2018, , .		2
860	Spectral-domain optical coherence tomography for conformal coating thickness measurement on printed circuit board. , 2018, , .		0
861	Patients' Behavior during Treatment in Patients Older than 90 Years Who Were Diagnosed with Neovascular Age-related Macular Degeneration. Journal of Retina, 2018, 3, 57-62.	0.1	0
862	Long-Term Visual Outcomes in Patients with Neovascular AMD Who Exhibited Visual Acuity of 0.1 or Worse at 5th Injection. Journal of Retina, 2018, 3, 64-70.	0.1	0
863	Clinical Course of Patients with Neovascular Age-related Macular Degeneration Who Experienced Visual Deterioration after Treatment despite Initially Good Visual Acuity. Journal of Retina, 2019, 4, 10-16.	0.1	0
864	Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration. Rossiiskii Oftal' mologicheskii Zhurnal, 2019, 12, 102-112.	0.1	0
865	Optical coherence tomography angiography in type 3 neovascularization. , 2020, , 321-341.		0
866	Clinical Outcomes after Switching from As-needed to Proactive Injections in the Neovascular Age-related Macular Degeneration. Journal of Korean Ophthalmological Society, 2020, 61, 630-638.	0.0	0

#	ARTICLE	IF	CITATIONS
867	Predictors of Retinal Pigment Epithelial Tears in Exudative Macular Degeneration with High Pigment Epithelial Detachment. <i>Journal of Korean Ophthalmological Society</i> , 2020, 61, 755-764.	0.0	1
869	Health Promotion, Audit, Research and Evidence-Based Medicine. , 2020, , 189-220.		0
871	Management Strategies for Neovascular AMD. , 2020, , 99-108.		0
872	TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands. <i>BMJ Open Ophthalmology</i> , 2020, 5, e000588.	0.8	0
873	Reading Centers for Clinical Trials of Choroidal Neovascularization (CNV): Present Role and Future Opportunities. , 2020, , 317-328.		0
874	Comparison of two different treatment regimensâ€™ efficacy in neovascular age-related macular degeneration in Turkish populationâ€™based on real life data-Bosphorus RWE Study Group. <i>International Journal of Ophthalmology</i> , 2020, 13, 104-111.	0.5	4
875	Results of Intravitreal Anti-VEGF Injection in Choroidal Neovascularizations Caused by Pathologies Other Than Age-Related Macular Degeneration. <i>Beyoglu Eye Journal</i> , 2020, 5, 129-134.	0.1	0
876	Visual Outcome and Treatment Frequency of Anti-VEGF Therapy Using the Treat-and-Extend and Treatment Cessation Regimen for Exudative Age-Related Macular Degeneration and Pachychoroid Neovascuopathy. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 4405-4418.	0.9	4
877	E-Health Applications in Ophthalmic Diseases. , 0, , 1088-1115.		0
879	Clinical Features of Eyes with Polypoidal Choroidal Vasculopathy and No Recurrence Over One Year. <i>Journal of Korean Ophthalmological Society</i> , 2020, 61, 1048-1056.	0.0	0
881	Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration. <i>Core Evidence</i> , 2008, 2, 273-94.	4.7	8
882	In vivo imaging of choroidal angiogenesis using fluorescence-labeled cationic liposomes. <i>Molecular Vision</i> , 2012, 18, 1045-54.	1.1	15
884	Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). <i>Transactions of the American Ophthalmological Society</i> , 2014, 112, 160-98.	1.4	20
885	Optical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based Analysis. <i>Ontario Health Technology Assessment Series</i> , 2014, 14, 1-64.	3.0	8
886	Recommendations of the treat-and-extend regimen for neovascular age-related macular degeneration: 2020 updates. <i>Hong Kong Journal of Ophthalmology: the Official Publication of the College of Ophthalmologists of Hong Kong = Xianggang Yan Ke Xue Kan: Xianggang Yan Ke Yi Xue Yuan</i> , 2022, 25, 39-46.	0.3	1
887	Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression. <i>Journal of Clinical Medicine</i> , 2022, 11, 325.	1.0	13
888	Chromatic Full-Field Stimulus Thresholds in Patients with Treatment-Naive Age-Related Macular Degeneration. <i>Clinical Ophthalmology</i> , 2022, Volume 16, 223-229.	0.9	3
889	Difference Between the Incidence of Retinal Fluid Subtypes and Their Association with Visual Outcomes According to the Types of Macular Neovascularization in a Korean Population. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2022, 38, 261-268.	0.6	4

#	ARTICLE	IF	CITATIONS
890	Genotyping of Clinical Parameters in Age-Related Macular Degeneration. <i>Clinical Ophthalmology</i> , 2022, Volume 16, 517-529.	0.9	1
891	Masking of macular neovascular membranes by subretinal hyperreflective material on optical coherence tomography angiography. <i>European Journal of Ophthalmology</i> , 2022, , 112067212210853.	0.7	0
892	Fluid dynamics between injections in incomplete anti-VEGF responders within neovascular age-related macular degeneration: a prospective observational study. <i>International Journal of Retina and Vitreous</i> , 2022, 8, 19.	0.9	2
893	SYSTEMATIC CORRELATION OF CENTRAL SUBFIELD THICKNESS WITH RETINAL FLUID VOLUMES QUANTIFIED BY DEEP LEARNING IN THE MAJOR EXUDATIVE MACULAR DISEASES. <i>Retina</i> , 2022, 42, 831-841.	1.0	10
894	Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy. <i>Therapeutic Advances in Ophthalmology</i> , 2022, 14, 251584142210833.	0.8	3
895	Age-related Macular Degeneration (AMD). , 2008, , 50-50.		55
896	OCT-angiography follow-up of choroidal neovascularization treated with treat- and- extend aflibercept regimen to avoid over-treatment. <i>European Journal of Ophthalmology</i> , 2022, , 112067212211022.	0.7	0
897	OCT-Derived Radiomic Features Predict Anti-VEGF Response and Durability in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology Science</i> , 2022, 2, 100171.	1.0	5
898	Outcome of Aflibercept-Bevacizumab Alternate Dosing in Neovascular Age-related Macular Degeneration with Limited Response to Aflibercept. <i>Journal of Korean Ophthalmological Society</i> , 2022, 63, 526-534.	0.0	0
899	Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2022, 260, 3781-3789.	1.0	5
900	The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD. , 2022, 63, 17.		7
901	Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
902	The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study. <i>PLoS ONE</i> , 2022, 17, e0271999.	1.1	2
903	A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
905	Biomaterials in Their Role in Creating New Approaches for the Delivery of Drugs, Proteins, Nucleic Acids, and Mammalian Cells in Safety Pharmacology. , 2022, , 1-27.		0
906	Research Trends and Hotspots of Retinal Optical Coherence Tomography: A 31-Year Bibliometric Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 5604.	1.0	0
907	Impact of Treating Age-Related Macular Degeneration before Visual Function Is Impaired. <i>Journal of Clinical Medicine</i> , 2022, 11, 5726.	1.0	0
908	Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. <i>Eye</i> , 2023, 37, 1758-1765.	1.1	6

#	ARTICLE	IF	CITATIONS
910	Morphological and functional retinal changes in neovascular age-related macular degeneration treated with intravitreal bevacizumab. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 4376.	0.5	0
911	Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema. <i>Cost Effectiveness and Resource Allocation</i> , 2022, 20, .	0.6	2
912	Relevance of Visual Acuity Measurement for Therapeutic Decisions in Age-Related Macular Degeneration. <i>Journal of Clinical Medicine</i> , 2023, 12, 522.	1.0	1
914	Relationship between ganglion cell complex thickness and vision in age-related macular degeneration treated with aflibercept. <i>European Journal of Ophthalmology</i> , 0, , 112067212211490.	0.7	1
915	Associations between Serial Intravitreal Injections and Dry Eye. <i>Ophthalmology</i> , 2023, 130, 509-515.	2.5	7
917	Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis. <i>Eye</i> , 2023, 37, 2855-2863.	1.1	1
919	The Effect of Intravitreal Bevacizumab Injection in Wet Age-Related Macular Degeneration Patients with Cataract Surgery. <i>Keimyung Medical Journal</i> , 0, , .	0.1	0